

AUTHOR INDEX FOR VOLUME 42

A

- Abood, M. E., *see* Kaminski, N. E., 736
 Abramovitz, M., *see* Vickers, P. J., 1014
 Abrams, M., *see* Yamamoto, N., 1109
 Abramson, J. J., *see* Zimányi, I., 1049
 Abramson, R., *see* Bhushan, A., 69
 Adam, M., *see* Vickers, P. J., 94
 Adams, M. E., *see* Cohen, C. J., 947
 Ades, A. M., *see* Mah, S. J., 217
 Ahluwalia, G., *see* Bondoc, L. L., Jr., 525
 Ahmad, S., Trepel, J. B., Ohno, S., Suzuki, K., Tsuruo, T., and Glazer, R. I. Role of protein kinase C in the modulation of multidrug resistance: Expression of the atypical γ isoform of protein kinase C does not confer increased resistance to doxorubicin, 1004
 Aiyar, N., *see* Nambi, P., 336
 Albers, F. J., *see* Becker, B. N., 817
 Anantharam, V., Bayley, H., Wilson, A., and Treistman, S. N. Differential effects of ethanol on electrical properties of various potassium channels expressed in oocytes, 499
 Andre, C., *see* Bourdi, M., 280
 Andrei, G., *see* Yamamoto, N., 1109
 Angellotti, T. P., *see* Porter, N. M., 872
 Ansanay, H., Sebben, M., Bockaert, J., and Dumuis, A. Characterization of homologous 5-hydroxytryptamine₁ receptor desensitization in colliculi neurons, 808
 Asano, Y., *see* Brach, M. A., 63

B

- Baba, N., *see* Yamamoto, N., 1109
 Baez, M., *see* Kursar, J. D., 549
 Bahouth, S. W. Effects of chemical and surgical sympathectomy on expression of β -adrenergic receptors and guanine nucleotide-binding proteins in rat submandibular glands, 971
 Bakthavachalam, V., *see* Baldessarini, R. J., 856
 Baldessarini, R. J., Kula, N. S., Campbell, A., Bakthavachalam, V., Yuan, J., and Neumeyer, J. L. Prolonged D₂ antidopaminergic activity of alkylating and nonalkylating derivatives of spiperone in rat brain, 856
 Balzarini, J., *see* Yamamoto, N., 1109
 Bansal, A., *see* Cascieri, M. A., 458
 Barber, R., *see* Prohl, M. A., 116
 Barbour, K. W., Hoganson, D. K., Berger, S. H., and Berger, F. G. A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells, 242
 Barden, N., *see* Pepin, M.-C., 991
 Barg, J., *see* Belcheva, M. M., 445
 Barredo, J., and Moran, R. G. Determinants of antifolate cytotoxicity: Folylpolyglutamate synthetase activity during cellular proliferation and development, 687
 Barrow, R. K., *see* Mourey, R. J., 619
 Barsh, G., *see* Link, R., 16
 Barturen, F., and Garcia-Sevilla, J. A. Long term treatment with desipramine increases the turnover of α_2 -adrenoceptors in the rat brain, 846
 Basile, A. S., Paul, I. A., Mirchevich, A., Kuijpers, G., and de Costa, B. Modulation of (+)-[³H]pentazocine binding to guinea pig cerebellum by divalent cations, 882
 Basu, H. S., *see* Ghoda, L., 302
 Battey, J. F., *see* Benya, R. V., 1058
 Bayley, H., *see* Anantharam, V., 499
 Beattie, K. L., *see* Ling, Y.-H., 802
 Beaune, P. H., *see* Bourdi, M., 280
 Becker, B. N., Gettys, T. W., Middleton, J. P., Olsen, C. L., Albers, F. J., Lee, S.-L., Fanburg, B. L., and Raymond, J. R. 8-Hydroxy-2-(di-*n*-propylamino)tetralin-responsive 5-hydroxytryptamine₁-like receptor expressed in bovine pulmonary artery smooth muscle cells, 817
 Beck-Sickinger, A. G., *see* Michel, M. C., 642
 Beddell, C. R., *see* Holmes, E., 922
 Belcheva, M. M., Barg, J., Gloeckner, C., Gao, X.-M., Chuang, D.-M., and Coscia, C. J. Antagonist-induced transient down-regulation of δ -opioid receptors in NG108-15 cells, 445
 Bell, G. I. *see* Rens-Domaino, 28
 Belloc, C., *see* Bourdi, M., 280
 Bensasson, R. V., Frederiksen, J., Rougée, M., Lexa, D. and Harrit, N. Correlations between the rate constant of singlet oxygen quenching by imidazole derivatives and anti-inflammatory activity in rats, 718
 Benveniste, M., and Mayer, M. L. Effect of extracellular pH on the potency of *N*-methyl-D-aspartic acid receptor competitive antagonists, 679
 Benya, R. V., Wada, E., Battey, J. F., Fathi, Z., Wang, L.-H., Mantey, S., Coy, D. H., and Jensen, R. T. Neuromedin B receptors retain functional expression when transfected into BALB 3T3 fibroblasts: Analysis of binding, kinetics, stoichiometry, modulation by guanine nucleotide-binding proteins, and signal transduction and comparison with natively expressed receptors, 1058
 Ber, E., *see* Cascieri, M. A., 458
 Berger, F. G., *see* Barbour, K. W., 242
 Berger, S. H., *see* Barbour, K. W., 242
 Bhatnagar, A., Liu, S.-Q., Petrash, J. M., and Srivastava, S. K. Mechanism of inhibition of aldose reductase by menadione (vitamin K₃), 917
 Bhushan, A., Abramson, R., Chiu, J.-F., and Tritton, T. R. Expression of *c-fos* in human and murine multidrug resistant cells, 69
 Biagi, B. A., *see* Enyeart, J. J., 364
 Bidlack, J. M., *see* Gucker, S., 656
 Bienkowski, M. J., *see* Veldman, S. A., 439
 Billingsley, M. L., *see* Toggas, S. M., 44
 Birnbaumer, L., *see* Graf, R., 760
 Biser, P. S., *see* Roberts, M. I., 784
 Blair, I. A., *see* Wilson, A. L., 175
 Blakeman, D. P., *see* Petke, J. D., 294
 Blaxall, H. S., *see* Bylund, D. B., 1
 Bleakman, D., Rusin, K. I., Chard, P. S., Glaum, S. R., and Miller, R. J. Metabotropic glutamate receptors potentiate ionotropic glutamate responses in the rat dorsal horn, 192
 Bock, K. W., Gschaidmeier, H., Seidel, A., Baird, S., and Burchell, B. Mono- and diglucuronide formation chrysene and benzo(*a*)pyrene phenols by 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase (UGT1A1), 613
 Bockaert, J., *see* Ansanay, H., 808
 Bockaert, J., *see* Manzoni, O., 322
 Bolotina, V., Courtney, K. R., and Khodorov, B. Gate-dependent blockade of sodium channels by phenothiazine derivatives: Structure-activity relationships, 423
 Bondoc, L. L., Jr., Ahluwalia, G., Cooney, D. A., Hartman, N. R., Johns, D. G., and Fridland, A. Metabolic pathways for the activa-

- tion of the antiviral agent 2',3'-dideoxyguanosine in human lymphoid cells, 525
- Bonner, F. W., *see* Holmes, E., 922
- Borden, L. A., *see* Smith, K. E., 563
- Borgono, C., *see* Israel, Y., 711
- Bossard, G., *see* Yamamoto, N., 1109
- Boteju, L. W., *see* Cheon, H. G., 82
- Bourdi, M., Gautier, J.-C., Mircheva, J., Larrey, D., Guillozo, A., Andre, C., Belloc, C., and Beaune, P. H. Anti-liver microsomes autoantibodies and dihydralazine-induced hepatitis: Specificity of autoantibodies and inductive capacity of the drug, 280
- Brach, M. A., Gruss, H.-J., Riedel, D., Asano, Y., de Vos, S., and Herrmann, F. Effect of antiinflammatory agents on synthesis of MCP-1/JE transcripts by human blood monocytes, 63
- Branchek, T. A., *see* Smith, K. E., 563
- Branchek, T. A., *see* Zgombick, J. M., 180
- Briley, E. M., *see* Felder, C. C., 838
- Brooker, G., *see* de Erausquin, G., 407
- Bryan, H., *see* Nambi, P., 336
- Buck, E., *see* Zimányi, I., 1049
- Burnham, W. Mc., *see* Francis, J., 1097
- Burns, D., *see* Cascieri, M. A., 458
- Burris, K. D., and Sanders-Bush, E. Unsurmountable antagonism of brain 5-hydroxytryptamine₂ receptors by (+)-lysergic acid diethylamide and bromo-lysergic acid diethylamide, 826
- Buschauer, A., *see* Seifert, R., 227, 235
- Butcher, R. W., *see* Proll, M. A., 116
- Butler, J., *see* Gibson, N. W., 531
- Butler, R., *see* Rhodes, D. G., 596
- Butt, E., *see* Sekhar, K. R., 103
- Bylund, D. B., Blaxall, H. S., Iversen, L. J., Caron, M. G., Lefkowitz, R. J., and Lomasney, J. W. Pharmacological characteristics of α_2 -adrenergic receptors: comparison of pharmacologically defined subtypes with subtypes identified by molecular cloning, 1
- C**
- Calvo, S., González-García, C., and Ceña, V. Axoplasmic transport of [³H] ouabain binding sites and catecholamine secretion from an adrenergic nerve trunk, 141
- Campbell, A., *see* Baldessarini, R. J., 856
- Campillo, M., *see* Giraldo, J., 373
- Caron, M. G., *see* Bylund, D. B., 1
- Caron, M. G., *see* Giros, B., 383
- Carter, D. B., *see* Petke, J. D., 294
- Cascieri, M. A., Ber, E., Fong, T. M., Sadowski, S., Bansal, A., Swain, C., Seward, E., Frances, B., Burns, D., and Strader, C. D. Characterization of the binding of a potent, selective, radioiodinated antagonist to the human neurokinin-1 receptor, 458
- Casida, J. E., *see* Hawkinson, J. E., 1069
- Catterall, W. A., *see* Duff, H. J., 570
- Ceña, V., *see* Calvo, S., 141
- Cerny, J., Foster, S. A., and Cheng, Y.-C. Cell-protecting effect against herpes simplex virus-1 and cellular metabolism of 9-(2-phosphorylmethoxyethyl)adenine in HeLa S3 cells, 537
- Chakinala, M. M., *see* Sekhar, K. R., 103
- Chan, J. Y., *see* Ling, Y.-H., 802
- Chang, R. S. L., *see* Chen, T. B., 1077
- Chard, P. S., *see* Bleakman, D., 192
- Charleson, S., *see* Vickers, P. J., 94, 1014
- Charra, M., *see* Fossé, P., 590
- Chavkin, C., *see* Connor, M. A., 471
- Chen, S., and Liu, X.-F. Suggested mechanism for the modulation of the activity of NAD(P)H:quinone acceptor oxidoreductase (DT-diaphorase) by menadione: Interpretation of the effect of menadione on 5'-[p-(fluorosulfonyl)benzoyl]adenosine labeling of rat liver NAD(P)H:quinone acceptor oxidoreductase, 545
- Chen, T. B., Lotti, V. J., and Chang, R. S. L. Characterization of the binding of [³H]L-158,809: A new potent and selective nonpeptide angiotensin II receptor (AT₁) antagonist radioligand, 1077
- Cheng, Y.-c., *see* Cerny, J., 537
- Cheon, H. G., Boteju, L. W., and Hanna, P. E. Affinity alkylation of hamster hepatic arylamine *N*-acetyltransferases: Isolation of a modified cysteine residue, 82
- Chiu, J.-F., *see* Bhushan, A., 69
- Cho, A. K., *see* Kumagi, Y., 695
- Choudhary, M. S., Craig, S., and Roth, B. L. Identification of receptor domains that modify ligand binding to 5-hydroxytryptamine₂ and 5-hydroxytryptamine_{1c} serotonin receptors, 627
- Christophe, J., *see* Robberecht, P., 347
- Chruscinski, A., *see* Link R., 16
- Chuang, D.-M., Gao, X.-M., and Paul, S. M. *N*-Methyl-D-aspartate exposure blocks glutamate toxicity in cultured cerebellar granule cells, 210
- Chuang, D.-M., *see* Belcheva, M. M., 445
- Clark, R. B., *see* Proll, M. A., 116
- Clarke, S. D., *see* Kletzien, R. F., 558
- Codina, J., *see* Graf, R., 760
- Coffino, P., *see* Ghoda, L., 302
- Cohen, C. J., Ertel, E. A., Smith, M. M., Venema, V. J., Adams, M. E., and Leibowitz, M. D. High affinity block of myocardial L-type calcium channels by the spider toxin ω -Agatoxin IIIA: Advantages over 1,4-dihydropyridines, 947
- Cohen, M. L., *see* Kursar, J. D., 549
- Connor, M. A., and Chavkin, C. Ionic zinc may function as an endogenous ligand for the haloperidol-sensitive σ_2 receptor in rat brain, 471
- Coon, M. J., *see* Ding, X., 1027
- Cooney, D. A., *see* Bondoc, L. L., Jr., 525
- Coppolino, M. G., *see* Vickers, P. J., 94
- Corbin, J. D., *see* Sekhar, K. R., 103
- Coscia, D. J., *see* Belcheva, M. M., 445
- Costa, E., *see* de Erausquin, G., 407
- Costa, T., *see* Ogino, Y., 6
- Courtney, K. R., *see* Bolotina, V., 423
- Covey, D. F., *see* Rodgers-Neame, N. T., 952
- Coward, J. K., *see* Rhee, M. S., 909
- Cox, J. A., *see* Stein, E., 864
- Coy, D. H., *see* Benya, R. V., 1058
- Cragoe, E. J., Jr., *see* Wilson, A. L., 175
- Craig, S., *see* Choudhary, M. S., 627
- Creveling, C. R., *see* Gusovsky, F., 1104
- Curry, K., *see* Manzoni, O., 322
- D**
- Daly, J. W., *see* Gusovsky, F., 1104
- Dasso, L. L. T., and Taylor, C. W. Different calcium-mobilizing receptors share the same guanine nucleotide-binding protein pool in hepatocytes, 453
- Daunt, D., *see* Link, R., 16
- Dawson, T. M., *see* Mourey, R. J., 619
- Debyser, Z., *see* Yamamoto, N., 1109
- De Clerq, E., *see* Yamamoto, N., 1109
- de Costa, B., *see* Basile, A. S., 882
- de Erausquin, G., Brooker, G., Costa, E., and Wojcik, W. J. Stimulation of high affinity γ -aminobutyric acid_B receptors potentiates the depolarization-induced increase of intraneuronal ionized calcium content in cerebellar granule neurons, 407
- De Neef, P., *see* Robberecht, P., 347
- Denison, M. S., *see* Harper, P. A., 603
- de Vos, S., *see* Brach, M. A., 63
- Dichter, M. A., *see* Williams, K., 147
- Diederich, M., *see* Eschenhagen, T., 773
- Ding, X., Peng, H.-M., and Coon, M. J. Cytochromes P450 NMa, NMb (2G1), and LM4 (1A2) are differentially expressed during development in rabbit olfactory mucosa and liver, 1027
- Di Paolo, T., *see* Morissette, M., 480
- Doods, H., *see* Michel, M. C., 642

- Dooley, T. P., *see* Hirshey, S. J., 257
 Drummond, A. H., *see* Varney, M. A., 671
 Duff, H. J., Offord, J., West, J., and Catterall, W. A. Class I and IV antiarrhythmic drugs and cytosolic calcium regulate mRNA encoding the sodium channel α subunit in rat cardiac muscle, 570
 Dumuis, A., *see* Ansanay, H., 808
 Dürr, H., *see* Michel, M. C., 642

E

- El-Fakahany, E. E., *see* Hu, J., 311
 Elliott, J. *see* Nambi, P., 336
 Ellis, J., and Seidenberg, M. Two allosteric modulators interact at a common site on cardiac muscarinic receptors, 638
 El Mestikawy, S., *see* Giros, B., 383
 Enna, A. E., *see* Mourey, R. J., 619
 Enyeart, J. J., Biagi, B. A., and Mlinar, B. Preferential block of T-type calcium channels by neuroleptics in neural crest-derived rat and human C cell lines, 364
 Ertel, E. A., *see* Cohen, C. J., 947
 Esbenshade, T. A., Han, C., Theroux, T. L., Granneman, J. G., and Minneman, K. P. Coexisting β_1 - and atypical β -adrenergic receptors cause redundant increases in cyclic AMP in human neuroblastoma cells, 753
 Eschenhagen, T., Mende, U., Diederich, M., Nose, M., Schmitz, W., Scholz, H., Schulte Am Esch, J., Warnholtz, A., and Schäfer, H. Long term β -adrenoceptor-mediated up-regulation of $G_{i\alpha}$ and $G_{o\alpha}$ mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart, 773
 Evans, D. L., *see* Lahti, R. A., 432
 Evans, J. F., *see* Vickers, P. J., 94

F

- Falany, C. N., *see* Hirshey, S. J., 257
 Fanburg, B. L., *see* Becker, B. N., 817
 Farber, J. L., *see* Rothman, R. J., 703
 Fathi, Z., *see* Benya, R. V., 1058
 Felder, C. C., Veluz, J. S., Williams, H. L., Briley, E. M., and Matsuda, L. A. Cannabinoid agonists stimulate both receptor- and nonreceptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones, 838
 Figur, L. M., *see* Lahti, R. A., 432
 Fisher, S. K., McEwen, E. L., Lovell, S. C., and Landon, R. E. Cyclic AMP potentiates receptor-stimulated phosphoinositide hydrolysis in human neuroepithelioma cells, 340
 Fleming, W. W., *see* Roberts, M. I., 784
 Fluharty, S. J., *see* Mah, S. H., 217
 Foellmi, L. A., *see* Kletzien, R. F., 558
 Fong, T. M., *see* Cascieri, M. A., 458
 Forray, C., *see* Hu, J., 311
 Fossé, P., René, B., Charra, M., Paoletti, C., and Saucier, J.-M. Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: Structure-activity relationship, 590
 Fossom, L. H., Sterling, C. R., and Tank, A. W. Regulation of tyrosine hydroxylase gene transcription rate and tyrosine hydroxylase mRNA stability by cyclic AMP and glucocorticoid, 898
 Foster, S. A., *see* Cerny, J., 537
 Fraeyman, N., *see* Van Ermen, A., 649
 Frances, B., *see* Cascieri, M. A., 458
 Francis, J., and Burnham, W. M. [3 H]Phenytoin identifies a novel anticonvulsant-binding domain on voltage-dependent sodium channels, 1097
 Francis, S. H., *see* Sekhar, K. R., 103
 Fraser, C. M., *see* Ogino, Y., 6
 Frederiksen, J., *see* Bensasson, R. V., 718
 Fridland, A., *see* Bondoc, L. L., 525

G

- Gaida, W., *see* Michel, M. C., 642
 Galivan, J., *see* Rhee, M. S., 909
 Ganousis, L. G., Goon, D., Zyglewska, T., Wu, K. K., Ross, D. Cell-specific metabolism in mouse bone marrow stroma: Studies of activation and detoxification of benzene metabolites, 1118
 Gao, X.-M., *see* Belcheva, M. M., 445
 Gao, X.-M., *see* Chuang, D.-M., 210
 García-Sáinz, J. A., *see* Torres-Márquez, M. E., 403
 Garcia-Sevilla, J. A., *see* Barturen, F., 846
 Garrison, J. C., *see* Liang, M., 743
 Gautier, J.-C., *see* Bourdi, M., 280
 Gettys, T. W., *see* Becker, B. N., 817
 Ghoda, L., Basu, H. S., Porter, C. W., Marton, L. J., and Coffino, P. Role of ornithine decarboxylase suppression and polyamine depletion in the antiproliferative activity of polyamine analogs, 302
 Giannone, J. V., *see* Harper, P. A., 603
 Gibson, N. W., Hartley, J. A., Butler, J., Siegel, D., and Ross, D. Relationship between DT-diaphorase-mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity, 531
 Giraldo, J., Martín, M., Campillo, M., and Pardo, L. Theoretical studies on the histamine H_2 receptor: Molecular mechanism of action of antagonists, 373
 Giros, B., El Mestikawy, S., Godinot, N., Zheng, K., Han, H., Yang-Feng, T., and Caron, M. G. Cloning, pharmacological characterization, and chromosome assignment of the human dopamine transporter, 383
 Glaum, S. R., *see* Bleakman, D., 192
 Glazer, R. I., *see* Ahmad, S., 1004
 Gloeckner, C., *see* Belcheva, M. M., 445
 Godfrey, P. P., *see* Varney, M. A., 671
 Godinot, N., *see* Giros, B., 383
 Goka, T. J., *see* Proll, M. A., 116
 González-Espinosa, C., *see* Torres-Márquez, M. E., 403
 Gonzalez-Garcia, C., *see* Calvo, S., 141
 Goon, D., *see* Ganousis, L. G., 1118
 Gorospe, E., *see* Leonhardt, S., 328
 Goto, J., *see* Imura, R., 964
 Gourlet, P., *see* Robberecht, P., 347
 Graf, R., Codina, J., and Birnbaumer, L. Peptide inhibitors of ADP-ribosylation by pertussis toxin are substrates with affinities comparable to those of the trimeric GTP-binding proteins, 760
 Granneman, J. G., Lahnert, K. N., and Rao, D. D. Rodent and human β_3 -adrenergic receptor genes contain an intron within the protein-coding block, 964
 Granneman, J. G., *see* Esbenshade, T. A., 753
 Green, R. D., *see* Ma, H., 831
 Grider, J. R., *see* Kiemmerle, J. F., 1090
 Gruss, H.-J., *see* Brach, M. A., 63
 Gucker, S., and Bidlack, J. M. Protein kinase C activation increases the rate and magnitude of agonist-induced δ -opioid receptor down-regulation in NG108-15 cells, 656
 Guillouzo, A., *see* Bourdi, M., 280
 Gusovsky, F., Padgett, W. L., Creveling, C. R., and Daly, J. W. Interaction of pumiliotoxin B with an "alkaloid-binding domain" on the voltage-dependent sodium channel, 1104

H

- Hales, T. G., Kim, H., Longoni, B., Olsen, R. W., and Tobin, A. J. Immortalized hypothalamic GT1-7 neurons express functional γ -aminobutyric acid type A receptors, 197
 Hamilton, B. J., *see* Petke, J. D., 294
 Han, C., *see* Esbenshade, T. A., 753
 Han, H., *see* Giros, B., 383
 Hanna, P. E., *see* Cheon, H. G., 82
 Hanna, P. M., *see* Kadiiska, M. B., 723

- Harper, P. A., Giannone, J. V., Okey, A. B., and Denison, M. S. *In vitro* transformation of the human Ah receptor and its binding to a dioxin response element, 603
- Harris, P. K. W., *see* Kletzien, R. F., 558
- Harrit, N., *see* Bensasson, R. V., 718
- Hartig, P. R., *see* Smith, K. E., 563
- Hartig, P. R., *see* Zgombick, J. M., 180
- Hartley, J. A., *see* Gibson, N. W., 531
- Hartman, N. R., *see* Bondoc, L. L., 525
- Hatchett, R. J., *see* Sekhar, K. R., 103
- Hawkinson, J. E., and Casida, J. E. Binding kinetics of γ -aminobutyric acid₁ receptor noncompetitive antagonists: Trioxabicyclooctane, dithiane, and cyclodiene insecticide-induced slow transition to blocked chloride channel conformation, 1069
- Haynes, A. R., *see* Wangoo, A., 584
- Heinrikson, R. L., *see* Hirshey, S. J., 257
- Henson, G., *see* Yamamoto, N., 1109
- Herbette, L., *see* Rhodes, D. G., 596
- Hernandez, L., *see* Kadiiska, M. B., 723
- Herrmann, F., *see* Brach, M. A., 63
- Hertel, L., *see* Shewach, D. S., 518
- Hidaka, H., *see* Li, G., 489
- Hirshey, S. J., Dooley, T. P., Reardon, I. M., Heinrikson, R. L., and Falany, C. N. Sequence analysis, *in vitro* translation, and expression of the cDNA for rat liver minoxidil sulfotransferase, 257
- Höer, A., *see* Seifert, R., 227, 235
- Hoffman, B. J., *see* Leonhardt, S., 328
- Hoganson, D. K., *see* Barbour, K. W., 242
- Hollenberg, M. D., Yang, S.-G., Laniyonu, A. A., Moore, G. J., and Saifeddine, M. Action of thrombin receptor polypeptide in gastric smooth muscle: Identification of a core pentapeptide retaining full thrombin-mimetic intrinsic activity, 186
- Holmes, E., Bonner, F. W., Sweatman, B. C., Lindon, J. C., Beddell, C. R., Rahr, E., and Nicholson, J. K. Nuclear magnetic resonance spectroscopy and pattern recognition analysis of the biochemical processes associated with the progression of and recovery from nephrotoxic lesions in the rat induced by mercury(II) chloride and 2-bromoethanamine, 922
- Hosoya, M., *see* Yamamoto, N., 1109
- Hu, J., Wang, S.-Z., Forray, C., and El-Fakahany, E. E. Complex allosteric modulation of cardiac muscarinic receptors by protamine: Potential model for putative endogenous ligands, 311
- Hu, Y., *see* Rodgers-Neame, N. T., 952
- ### I
- Im, H. K., *see* Petke, J. D., 294
- Im, W. B., *see* Petke, J. D., 294
- Imura, R., Sano, T., Goto, J., Yamada, K., and Matsuda, Y. Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors, 982
- Isenberg, K. E., *see* Rodgers-Neame, N. T., 952
- Israel, Y., Macdonald, A., Niemelä, O., Zamel, D., Shami, E., Zywulko, M., Klajner, F., and Borgono, C. Hypersensitivity to acetaldehyde-protein adducts, 711
- Iversen, L. J., *see* Bylund, D. B., 1
- ### J
- Jackson, B., *see* Perich, R. B., 286
- Jacobsen, E. J., *see* Petke, J. D., 294
- Jacobson, K. A., *see* Palmer, T. M., 391
- Jacobson, K. A., Stiles, G. L., and Ji, X.-D. Chemical modification and irreversible inhibition of striatal A_{2A} adenosine receptors, 123
- Jakobs, K. H., *see* Wieland, T., 731
- Jani, J. P., *see* Morris, G., 57
- Jastorff, B., *see* Sekhar, K. R., 103
- Jensen, R. T., *see* Benya, R. V., 1058
- Ji, X.-D., *see* Jacobson, K. A., 123
- Jin, W., Lee, N. M., Loh, H. H., and Thayer, S. A. Dual excitatory and inhibitory effects of opioids on intracellular calcium in neuroblastoma × glioma hybrid NG108-15 cells, 1083
- Johns, D. G., *see* Bondoc, L. L., 525
- Johnston, C. I., *see* Perich, R. B., 286
- Jones, G. S., Jr., *see* Xie, Y., 356
- Jung, G., *see* Michel, M. C., 642
- ### K
- Kadiiska, M. B., Hanna, P. M., Hernandez, L., and Mason, R. P. *In vivo* evidence of hydroxyl radical formation after acute copper and ascorbic acid intake: Electron spin resonance spin-trapping investigation, 723
- Kaliszan, R., Noctor, T. A. G., and Wainer, I. W. Stereochemical aspects of benzodiazepine binding to human serum albumin. II. Quantitative relationships between structure and enantioselective retention in high performance liquid affinity chromatography, 512
- Kaliszan, R., *see* Noctor, T. A. G., 506
- Kamboj, R. K., Schoepp, D. D., Nutt, S., Shekter, L., Korczak, B., True, R. A., Zimmerman, D. M., and Wosnick, M. A. Molecular structure and pharmacological characterization of humEAA2, a novel human kainate receptor subunit, 10
- Kaminski, N. E., Abood, M. E., Kessler, F. K., Martin, B. R., and Schatz, A. Identification of a functionally relevant cannabinoid receptor on mouse spleen cells that is involved in cannabinoid-mediated immune modulation, 736
- Kanetoshi, A., Ward, A. M., May, B. K., and Rifkind, A. B. Immunochemical identity of the 2,3,7,8-tetrachlorodibenzo-*p*-dioxin- and β -naphthoflavone-induced cytochrome P-450 arachidonic acid epoxigenases in chick embryo liver: Distinction from the ω -hydroxylase and the phenobarbital-induced epoxigenase, 1020
- Katumi, S., *see* Nishizaki, T., 152
- Kellum, J. M., *see* Kuemmerle, J. F., 1090
- Kessler, F. K., *see* Kaminski, N. E., 736
- Khodorov, B., *see* Bolotina, V., 423
- Kim, H., *see* Hales, T. G., 197
- Kim, S. G., and Kim, Y.-H. Gender-related expression of rat microsomal epoxide hydrolase during maturation: Post-transcriptional regulation, 75
- Kim, S. G. Transcriptional regulation of rat microsomal epoxide hydrolase gene by imidazole antimycotic agents, 273
- Kim, Y.-H., *see* Kim, S. G., 75
- Kimmett, S. M., Whitney, R. A., and Marks, G. S. Evidence for the stereoselective inhibition of chick embryo hepatic ferrochelatase by *N*-alkylated porphyrins. II, 307
- Klajner, F., *see* Israel, Y., 711
- Kletzien, R. F., Foellmi, L. A., Harris, P. K. W., Wyse, B. M., and Clarke, S. D. Adipocyte fatty acid-binding protein: Regulation of gene expression *in vivo* and *in vitro* by an insulin-sensitizing agent, 558
- Kobilka, B., *see* Link, R., 16
- König, M., *see* O'Carroll, A.-M., 939
- Koop, D. R., *see* Laethem, R. M., 958
- Korczak, L. B., *see* Kamboj, R. K., 10
- Krady, J. K., *see* Toggas, S. M., 44
- Kuemmerle, J. F., Martin, D. C., Murthy, K. S., Kellum, J. M., Grider, J. R., and Makhoul, G. M. Coexistence of contractile and relaxant 5-hydroxytryptamine receptors coupled to distinct signaling pathways in intestinal muscle cells: Convergence of the pathways on Ca²⁺ mobilization, 1090
- Kuijpers, G., *see* Basile, A. S., 882
- Kula, N. S., *see* Baldessarini, R. J., 856
- Kumagai, Y., Lin, L. Y., Philpot, R. M., Yamada, H., Oguri, K., Yoshimura, H., and Cho, A. K. Regiochemical differences in cytochrome P450 isozymes responsible for the oxidation of methylenedioxypheyl groups by rabbit liver, 695

- Kunze, D. L., and Rampe, D. Characterization of the effects of a new Ca^{2+} channel activator, FPL 64176, in GH₃ cells, 666
- Kursar, J. D., Nelson, D. L., Wainscott, D. B., Cohen, M. L., and Baez, M. Molecular cloning, functional expression, and pharmacological characterization of a novel serotonin receptor (5-hydroxytryptamine_{2F}) from rat stomach fundus, 549
- L**
- Labouesse, J., *see* Valeins, H., 1033
- Laetham, R. M., and Koop, D. R. Identification of rabbit cytochromes P450 2C1 and 2C2 as arachidonic acid epoxigenases, 958
- Lahnert, K. N., *see* Granneman, J. G., 964
- Lahti, R. A., Figur, L. M., Piercey, M. F., Ruppel, P. L., and Evans, D. L. Intrinsic activity determinations at the dopamine D2 guanine nucleotide-binding protein-coupled receptor: Utilization of receptor state binding affinities, 432
- Lambert, D. G., *see* Tobin, A. B., 1042
- Landon, R. E., *see* Fisher, S. K., 340
- Laniyonu, A. A., *see* Hollenberg, M. D., 186
- Larrey, D., *see* Bourdi, M., 280
- Law, S. F., and Reisine, T. Agonist binding to rat brain somatostatin receptors alters the interaction of the receptors with guanine nucleotide-binding regulatory proteins, 398
- Law, S. F., *see* Rens-Domiano, 28
- Lazarovici, P., *see* Rasouly, D., 35
- Lazo, J. S., *see* Morris, G., 57
- Lee, N. M., *see* Jin, W., 1083
- Lee, S.-L., *see* Becker, B. N., 817
- Leibowitz, M. D., *see* Cohen, C. J., 947
- Leonhardt, S., Gorospe, E., Hoffman, B. J., and Teitler, M. Molecular pharmacological differences in the interaction of serotonin with 5-hydroxytryptamine_{1C} and 5-hydroxytryptamine₂ receptors, 328
- Leslie, F. M., *see* Smith, J. A. M., 575
- Lester, D., *see* Rasouly, D., 35
- Lévesque, D., *see* Morissette, M., 480
- Levy, G. N., *see* Martell, K. J., 265
- Lexa, D., *see* Bensasson, R. V., 718
- Li, G., Hidaka, H., and Wollheim, C. B. Inhibition of voltage-gated Ca^{2+} channels and insulin secretion in HIT cells by the Ca^{2+} /calmodulin-dependent protein kinase II inhibitor KN-62: Comparison with antagonists of calmodulin and L-type Ca^{2+} channels, 489
- Liang, M., and Garrison, J. C. Epidermal growth factor activates phospholipase C in rat hepatocytes via a different mechanism from that in A431 or rat1hER cells, 743
- Liggett, S. B. Functional properties of the rat and human β_3 -adrenergic receptors: Differential agonist activation of recombinant receptors in Chinese hamster ovary cells, 634
- Limbird, L. L., *see* Wilson, A. L., 175
- Lin, L. Y., *see* Kumagai, Y., 695
- Linden, J., *see* Prater, M. R., 765
- Lindon, J. C., *see* Holmes, E., 922
- Ling, Y.-H., Chan, J. Y., Beattie, K. L., and Nelson, J. A. Consequences of 6-thioguanine incorporation into DNA on polymerase, ligase, and endonuclease reactions, 802
- Link, R., Daunt, D., Barsh, G., Chruscinski, A., and Kobilka, B. Cloning of two mouse genes encoding α_2 -adrenergic receptor subtypes and identification of a single amino acid in the mouse α_2 -C10 homolog responsible for an interspecies variation in antagonist binding, 16
- Liu, S.-Q., *see* Bhatnagar, A., 917
- Liu, X.-F., *see* Chen, S., 545
- Loh, H. H., *see* Jin, W., 1083
- Lolait, S. J., *see* O'Carroll, A.-M., 939
- Lomasney, J. W., *see* Bylund, D. B., 1
- Longoni, B., *see* Hales, T. G., 197
- Loring, R. H., *see* Xie, Y., 356
- Lotti, V. J., *see* Chen, T. B., 1077
- Loughlin, S. E., *see* Smith, J. A. M., 575
- Lovell, S. C., *see* Fisher, S. K., 340
- M**
- Ma, H., and Green, R. D. Modulation of cardiac cyclic AMP metabolism by adenosine receptor agonists and antagonists, 831
- Macchi, M., *see* Zgombick, J. M., 180
- Macdonald, A., *see* Israel, Y., 711
- MacDonald, R. L., *see* Porter, N. M., 872
- Macdonald, R. L., *see* Rock, D. M., 157
- Mack, M. M., *see* Zimányi, I., 1049
- Mah, S. J., Ades, A. M., Mir, R., Siemens, I. R., Williamson, J. R., and Fluharty, S. J. Association of solubilized angiotensin II receptors with phospholipase C- α in murine neuroblastoma NIE-115 cells, 217
- Mahan, L. C., *see* O'Carroll, A.-M., 939
- Makhlouf, G. M., *see* Kuemmerle, J. F., 1090
- Mancini, J. A., *see* Vickers, P. J., 94, 1014
- Mantey, S., *see* Benya, R. V., 1058
- Manzoni, O., Prezeau, L., Rassendren, F. A., Sladeczek, F., Curry, K., and Bockaert, J. Both enantiomers of 1-aminocyclopentyl-1,3-dicarboxylate are full agonists of metabotropic glutamate receptors coupled to phospholipase C, 322
- Marks, G. S., *see* Kimmett, S. M., 307
- Martell, K. J., Levy, G. N., and Weber, W. W. Cloned mouse *N*-acetyltransferases: Enzymatic properties of expressed *Nat-1* and *Nat-2* gene products, 265
- Martin, B. R., *see* Kaminski, N. E., 736
- Martin, D. C., *see* Kuemmerle, J. F., 1090
- Martin, M., *see* Giraldo, J., 373
- Marton, L. J., *see* Ghoda, L., 302
- Mason, R. P., *see* Kadiiska, M. B., 723
- Matsuda, L. A., *see* Felder, C. C., 838
- Matsuda, Y., *see* Imura, R., 964
- Matsuda, Y., *see* Rasouly, D., 35
- May, B. K., *see* Kanetoshi, A., 1020
- Mayer, M. L., *see* Benveniste, M., 679
- McEwen, E. L., *see* Fisher, S. K., 340
- Meeley, M. P., *see* Wang, H., 792
- Mende, U., *see* Eschenhagen, T., 773
- Mendelsohn, F. A. O., *see* Perich, R. B., 286
- Merle, M., *see* Valeins, H., 1033
- Mhatre, M. C., and Ticku, M. K. Chronic ethanol administration alters γ -aminobutyric acid_A receptor gene expression, 415
- Michel, M. C., Gaida, W., Beck-Sickinge, A. G., Wieland, H. A., Doods, H., Dürr, H., Jung, G., and Schnorrenberg, G. Further characterization of neuropeptide Y receptor subtypes using centrally truncated analogs of neuropeptide Y: Evidence for subtype-differentiating effects on affinity and intrinsic efficacy, 642
- Middleton, J. P., *see* Becker, B. N., 817
- Mignano, J. E., *see* Morris, G., 57
- Miledi, R., *see* Woodward, R. M., 165
- Miller, K. W., *see* Tonner, P. H., 890
- Miller, R. J., *see* Bleakman, D., 192
- Minneman, K. P., *see* Esbenshade, T. A., 753
- Mir, R., *see* Mah, S. H., 217
- Mircheva, J., *see* Bourdi, M., 280
- Mirkevich, A., *see* Basile, A. S., 882
- Mistry, J. S., *see* Morris, G., 57
- Mlinar, B., *see* Enyeart, J. J., 364
- Molinoff, P. B., *see* Unsworth, C. D., 464
- Molinoff, P. B., *see* Williams, K., 147
- Moore, G. J., *see* Hollenberg, M. D., 186
- Moran, R. G., *see* Barredo, J., 687
- Morissette, M., Lévesque, D., and Di Paolo, T. Effect of chronic estradiol treatment on brain dopamine receptor reappearance after irreversible blockade: An autoradiographic study, 480

- Morris, G., Mistry, J. S., Jani, J. P., Mignano, J. E., Sebt, S. M., and Lazo, J. S. Neutralization of bleomycin hydrolase by an epitope-specific antibody, 57
- Mourey, R. J., Dawson, T. M., Barrow, R. K., Enna, A. E., and Synder, S. H. [^3H]Noscipine binding sites in brain: Relationship to indoleamines and the phosphoinositide and adenylyl cyclase messenger systems, 619
- Munshi, R., *see* Prater, M. R., 765
- Murray, M. Metabolite intermediate complexation of microsomal cytochrome P450 2C11 in male rat liver by nortriptyline, 931
- Murrer, B. A., *see* Yamamoto, N., 1109
- Murthy, K. S., *see* Kuemmerle, J. F., 1090
- N**
- Nahorski, S. R., *see* Tobin, A. B., 1042
- Nakashima, H., *see* Yamamoto, N., 1109
- Nambi, P., Wu, H. L., Pullen, M., Aiyar, N., Bryan, H., and Elliott, J. Identification of endothelin receptor subtypes in rat kidney cortex using subtype-selective ligands, 336
- Nelson, D. L., *see* Kursar, J. D., 549
- Nelson, J. A., *see* Ling, Y.-H., 802
- Neumeyer, J. L., *see* Baldessarini, R. J., 856
- Newton, R., *see* Rhodes, D. G., 596
- Neyts, J., *see* Yamamoto, N., 1109
- Nicholson, J. K., *see* Holmes, E., 922
- Niemelä, O., *see* Israel, Y., 711
- Nishizaki, T., and Sumikawa, K. Tunicamycin increases desensitization of junctional and extrajunctional acetylcholine receptors expressed in *Xenopus* oocytes by a mechanism independent of *N*-glycosylation blocking, 152
- Noctor, T. A. G., Pham, C. D., Kaliszan, R., and Wainer, I. W. Stereochemical aspects of benzodiazepine binding to human serum albumin. I. Enantioselective high performance liquid affinity chromatographic examination of chiral and achiral binding interactions between 1,4-benzodiazepines and human serum albumin, 506
- Noctor, T. A. G., *see* Kaliszan, R., 512
- Nose, M., *see* Eschenhagen, T., 773
- Nutt, S., *see* Kamboj, R. K., 10
- O**
- O'Carroll, A.-M., Lolait, S. J., König, M., and Mahan, L. C. Molecular cloning and expression of a pituitary somatostatin receptor with preferential affinity for somatostatin-28, 939
- Offermanns, S., *see* Seifert, R., 227
- Offord, J., *see* Duff, H. J., 570
- Ogino, Y., Fraser, C. M., and Costa, T. Selective interaction of β_2 - and α_2 -adrenergic receptors with stimulatory and inhibitory guanine nucleotide-binding proteins, 6
- Oguri, K., *see* Kumagi, Y., 695
- Ohno, S., *see* Ahmad, S., 1004
- Okey, A. B., *see* Harper, P. A., 603
- Olianas, M. C., and Onali, P. Characterization of opioid receptors mediating stimulation of adenylate cyclase activity in rat olfactory bulb, 109
- Olsen, C. L., *see* Becker, B. N., 817
- Olsen, R. W., *see* Hales, T. G., 197
- Omicinski, C. J., Ramsden, R., Rampersaud, A., and Walz, F. G., Jr. Null phenotype for cytochrome P450 2B2 in the rat results from a deletion of its structural gene, 249
- Onali, P., *see* Olianas, M. C., 109
- O'Neill, G. P., *see* Vickers, P. J., 1014
- Oswald, R. E., *see* Ziegra, C. J., 203
- P**
- Padgett, W. L., *see* Gusovsky, F., 1104
- Palmer, T. M., Jacobson, K. A., and Stiles, G. L. Immunological identification of A_2 adenosine receptors by two antipeptide antibody preparations, 391
- Paoletti, C., *see* Fossé, P., 590
- Pardo, L., *see* Giraldo, J., 373
- Paul, I. A., *see* Basile, A. S., 882
- Paul, S. M., *see* Chuang, D.-M., 210
- Pauwels, R., *see* Yamamoto, N., 1109
- Paxton, D., *see* Perich, R. B., 286
- Peng, H.-M., *see* Ding, X., 1027
- Pepin, M.-C., Pothier, F., and Barden, N. Antidepressant drug action in a transgenic mouse model of the endocrine changes seen in depression, 991
- Perich, R. B., Jackson, B., Rogerson, F., Mendelsohn, F. A. O., Paxton, D., and Johnston, C. I. Two binding sites on angiotensin-converting enzyme: Evidence from radioligand binding studies, 286
- Perzeau, L., *see* Manzoni, O., 322
- Pessah, I. N., *see* Zimányi, I., 1049
- Petke, J. D., Im, H. K., Im, W. B., Blakeman, D. P., Pregenzer, J. F., Jacobsen, E. J., Hamilton, B. J., and Carter, D. B. Characterization of functional interactions of imidazoquinoline derivatives with benzodiazepine- γ -aminobutyric acid $_A$ receptors, 294
- Petrash, J. M., *see* Bhatnagar, A., 917
- Pham, C. D., *see* Noctor, T. A. G., 506
- Philpot, R. M., *see* Kumagi, Y., 695
- Picker, D., *see* Yamamoto, N., 1109
- Piercey, M. F., *see* Lahti, R. A., 432
- Polenzani, L., *see* Woodward, R. M., 165
- Porter, C. W., *see* Ghoda, L., 302
- Porter, N. M., Angelotti, T. P., Twyman, R. E., and MacDonald, R. L. Kinetic properties of $\alpha_1\beta_1$ γ -aminobutyric acid $_A$ receptor channels expressed in Chinese hamster ovary cells: Regulation by pentobarbital and picrotoxin, 872
- Pothier, F., *see* Pepin, M.-C., 991
- Prakash, C., *see* Wilson, A. L., 175
- Prater, M. R., Taylor, H., Munshi, R., and Linden, J. Indirect effect of guanine nucleotides on antagonist binding to A_1 adenosine receptors: Occupation of cryptic binding sites by endogenous vesicular adenosine, 765
- Pregenzer, J. F., *see* Petke, J. D., 294
- Proll, M. A., Clark, R. B., Goka, T. J., Barber, R., and Butcher, R. W. β -Adrenergic receptor levels and function after growth of S49 lymphoma cells in low concentrations of epinephrine, 116
- Pullen, M., *see* Nambi, P., 336
- R**
- Rahamim, E., *see* Rasouly, D., 35
- Rahr, E., *see* Holmes, E., 922
- Rampe, D., *see* Kunze, D. L., 666
- Rampersaud, A., *see* Omiecinski, C. J., 249
- Ramsden, R., *see* Omiecinski, C. J., 249
- Rao, D. D., *see* Granneman, J. G., 964
- Rasouly, D., Rahamim, E., Lester, D., Matsuda, Y., and Lazarovici, P. Staurosporine-induced neurite outgrowth in PC12 cells is independent of protein kinase C inhibition, 35
- Rassendren, F. A., *see* Manzoni, O., 322
- Raymond, J. R., *see* Becker, B. N., 817
- Reardon, I. M., *see* Hirshey, S. J., 257
- Regunathan, S., *see* Wang, H., 792
- Reis, D. J., *see* Wang, H., 792
- Reisine, T., *see* Law, S. F., 398
- Reisine, T., *see* Rens-Domiano, S., 28
- René, B., *see* Fossé, P., 590
- Rens-Domiano, S., Law, S. F., Yamada, Y., Seino, S., Bell, G. I., and Reisine, T. Pharmacological properties of two cloned somatostatin receptors, 28
- Reynolds, K. K., *see* Shewach, D. S., 518
- Rhee, M. S., Coward, J. K., and Galivan, J. Depletion of 5,10-methylenetetrahydrofolate and 10-formyltetrahydrofolate by methotrexate in cultured hepatoma cells, 909

- Rhodes, D. G., Newton, R., Butler, R., and Herbette, L. Equilibrium and kinetic studies of the interactions of salmeterol with membrane bilayers, 596
- Riedel, D., *see* Brach, M. A., 63
- Rifkind, A. B., *see* Kanetoshi, A., 1020
- Robberecht, P., Gourlet, P., De Neef, P., Woussen-Colle, M.-C., Vandermereers-Piret, M.-C., Vandermereers, A., and Christophe, J. Receptor occupancy and adenylate cyclase activation in AR 4-2J rat pancreatic acinar cell membranes by analogs of pituitary adenylate cyclase-activating peptides amino-terminally shortened or modified in position 1, 2, 3, 20, or 21, 347
- Roberts, M. I., Biser, P. S., Stadel, J. M., Taylor, D. A., and Fleming, W. W. Adenylyl cyclase and guanine nucleotide-binding proteins in supersensitive guinea pig ventricles, 784
- Rock, D. M., and Macdonald, R. L. Spermine and related polyamines produce a voltage-dependent reduction of *N*-methyl-D-aspartate receptor single-channel conductance, 157
- Rodgers-Neame, N. T., Covey, D. F., Hu, Y., Isenberg, K. E., and Zorumski, C. F. Effects of a benz[e]indene on γ -aminobutyric acid-gated chloride currents in cultured postnatal rat hippocampal neurons, 952
- Rogerson, F., *see* Perich, R. B., 286
- Romero-Avila, M. T., *see* Torres-Márquez, M. E., 403
- Ross, D., *see* Ganousis, L. G., 1118
- Ross, D., *see* Gibson, N. W., 531
- Roth, B. L., *see* Choudhary, M. S., 627
- Rothman, R. J., Serroni, A., and Farber, J. L. Cellular pool of transient ferric iron, chelatable by deferoxamine and distinct from ferritin, that is involved in oxidative cell injury, 703
- Rougée, M., *see* Bensasson, R. V., 718
- Ruppel, P. L., *see* Lahti, R. A., 432
- Rusin, K. I., *see* Bleakman, D., 192
- S**
- Sadowski, S., *see* Cascieri, M. A., 458
- Saifeddine, M., *see* Hollenberg, M. D., 186
- Sanders-Bush, E., *see* Burris, K. D., 826
- Sandig, P., *see* Scholz, J., 134
- Sano, T., *see* Imura, R., 964
- Saucier, J.-M., *see* Fossé, P., 590
- Schäfer, H., *see* Eschenhagen, T., 773
- Schatz, A. R., *see* Kaminski, N. E., 736
- Schechter, L. E., *see* Zgombick, J. M., 180
- Schmitz, W., *see* Eschenhagen, T., 773
- Schmitz, W., *see* Scholz, J., 134
- Schnorrenberg, G., *see* Michel, M. C., 642
- Schoepp, D. D., *see* Kamboj, R. K., 10
- Schols, D., *see* Yamamoto, N., 1109
- Scholz, H., *see* Eschenhagen, T., 773
- Scholz, H., *see* Scholz, J., 134
- Scholz, J., Troll, U., Sandig, P., Schmitz, W., Scholz, H., and Schulte Am Esch, J. Existence and α_1 -adrenergic stimulation of inositol polyphosphates in mammalian heart, 134
- Schulte Am Esch, J., *see* Eschenhagen, T., 773
- Schulte Am Esch, J., *see* Scholz, J., 134
- Schunack, W., *see* Seifert, R., 227
- Schwaner, I., *see* Seifert, R., 235
- Sebben, M., *see* Ansanay, H., 808
- Sebti, S. M., *see* Morris, G., 57
- Seeburg, P. H., *see* Stein, E., 864
- Sei, Y., *see* Wong, G., 996
- Seidenberg, M., *see* Ellis, J., 638
- Seifert, R., Höer, A., Offermanns, S., Buschauer, A., and Schunack, W. Histamine increases cytosolic Ca^{2+} in dibutyryl-cAMP-differentiated HL-60 cells via H_1 receptors and is an incomplete secretagogue, 227
- Seifert, R., Höer, A., Schwaner, I., and Buschauer, A. Histamine increases cytosolic Ca^{2+} in HL-60 promyelocytes predominantly via H_2 receptors with an unique agonist/antagonist profile and induces functional differentiation, 235
- Seino, S., *see* Rens-Domiano, 28
- Sekhar, K. R., Hatchett, R. J., Shabb, J. B., Wolfe, L., Francis, S. H., Wells, J. N., Jastorff, B., Butt, E., Chakinala, M. M., and Corbin, J. D. Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type $\text{I}\alpha$, compared with type $\text{I}\beta$, cGMP-dependent protein kinase, 103
- Serroni, A., *see* Rothman, R. J., 703
- Seward, E., *see* Cascieri, M. A., 458
- Shabb, J. B., *see* Sekhar, K. R., 103
- Shami, E., *see* Israel, Y., 711
- Shaw, R. J., *see* Wangoo, A., 584
- Shekter, L., *see* Kamboj, R. K., 10
- Shewach, D. S., Reynolds, K. K., and Hertel, L. Nucleotide specificity of human deoxycytidine kinase, 518
- Siegel, D., *see* Gibson, N. W., 531
- Siemens, I. R., *see* Mah, S. H., 217
- Skolnick, P., *see* Wong, G., 996
- Sladeczek, F., *see* Manzoni, O., 322
- Smith, J. A. M., Loughlin, S. E., and Leslie, F. M. κ -Opioid inhibition of [^3H]dopamine release from rat ventral mesencephalic dissociated cell cultures, 575
- Smith, K. E., Borden, L. A., Wang, C.-H. D., Hartig, P. R., Branchek, T. A., and Weinschank, R. L. Cloning and expression of a high affinity taurine transporter from rat brain, 563
- Smith, Mc. M., *see* Cohen, C. J., 947
- Snoeck, R., *see* Yamamoto, N., 1109
- Snyder, S. H., *see* Mourey, R. J., 619
- Sorooshain, M., *see* Wangoo, A., 584
- Srivastava, S. K., *see* Bhatnagar, A., 917
- Stadel, J. M., *see* Roberts, M. I., 784
- Stein, E., Cox, J. A., Seeburg, P. H., and Verdoorn, T. A. Complex pharmacological properties of recombinant α -amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes, 864
- Sterling, C. R., *see* Fossom, L. H., 898
- Stiles, G. L., *see* Jacobson, K. A., 123
- Stiles, G. L., *see* Palmer, T. M., 391
- Strader, C. D., *see* Cascieri, M. A., 458
- Sutcliffe, S. P., *see* Wangoo, A., 584
- Suzuki, K., *see* Ahmad, S., 1004
- Swain, C., *see* Cascieri, M. A., 458
- Sweatman, B. C., *see* Holmes, E., 922
- T**
- Tank, A. W., *see* Fossom, L. H., 898
- Taylor, C. W., *see* Dasso, L. L. T., 453
- Taylor, D. A., *see* Roberts, M. I., 784
- Taylor, H., *see* Prater, M. R., 765
- Teitler, M., *see* Leonhardt, S., 328
- Thayer, S. A., *see* Jin, W., 1083
- Theobald, B., *see* Yamamoto, N., 1109
- Theroux, T. L., *see* Esbenshade, T. A., 753
- Ticku, M. K., *see* Mhatre, M. C., 415
- Tobin, A. B., Lambert, D. G., and Nahorski, S. R. Rapid desensitization of muscarinic m_3 receptor-stimulated polyphosphoinositide responses, 1042
- Tobin, A. J., *see* Hales, T. G., 197
- Toggas, S. M., Krady, J. K., and Billingsley, M. L. Molecular neurotoxicology of trimethyltin: Identification of stannin, a novel protein expressed in trimethyltin-sensitive cells, 44
- Tonner, P. H., Wood, S. C., and Miller, K. W. Can nicotine self-inhibition account for its low efficacy at the nicotinic acetylcholine receptor from *Torpedo*?, 890
- Torres-Márquez, M. E., Romero-Avila, M. T., González-Espinosa, C., and García-Sáinz, J. A. Characterization of rat white fat cell $\alpha_{1\text{B}}$ -adrenoceptors, 403
- Treisman, S. N., *see* Anantharam, V., 499
- Trepel, J. B., *see* Ahmad, S., 1004

- Tritton, T. R., *see* Bhushan, A., 69
Troll, U., *see* Scholz, J., 134
True, R. A., *see* Kamboj, R. K., 10
Tsuruo, T., *see* Ahmad, S., 1004
Twyman, R. E., *see* Porter, N. M., 872

U

- Unsworth, C. D., and Molinoff, P. B. Regulation of the 5-hydroxytryptamine_{1B} receptor in opossum kidney cells after exposure to agonists, 464

V

- Valeins, H., Merle, M., and Labouesse, J. Pre-steady state study of β -adrenergic and purinergic receptor interaction in C6 cell membranes: Undelayed balance between positive and negative coupling to adenylyl cyclase, 1033
Vandermeers, A., *see* Robberecht, P., 347
Vandermeers-Piret, M.-C., *see* Robberecht, P., 347
Van de Velde, E., *see* Van Ermen, A., 649
Van Ermen, A., Van de Velde, E., Vanscheeuwijck, P., and Fraeyman, N. Influence of age on β_1 - and β_2 -adrenergic receptors in rat liver, 649
Vanscheeuwijck, P., *see* Van Ermen, A., 649
Varney, M. A., Godfrey, P. P., Drummond, A. H., and Watson, S. P. Chronic lithium treatment inhibits basal and agonist-stimulated responses in rat cerebral cortex and GH₃ pituitary cells, 671
Veldman, S. A., and Bienkowski, M. J. Cloning and pharmacological characterization of a novel human 5-hydroxytryptamine_{1D} receptor subtype, 439
Veluz, J. S., *see* Felder, C. C., 838
Venema, V. J., *see* Cohen, C. J., 947
Verdoorn, T. A., *see* Stein, E., 864
Vickers, P. J., Adam, M., Charleson, S., Coppolino, M. G., Evans, J. F., and Mancini, J. A. Identification of amino acid residues of 5-lipoxygenase-activating protein essential for the binding of leukotriene biosynthesis inhibitors, 94
Vickers, P. J., O'Neill, G. P., Mancini, J. A., Charleson, S., and Abramovitz, M. Cross-species comparison of 5-lipoxygenase-activating protein, 1014

W

- Wada, E., *see* Benya, R. V., 1058
Wainer, I. W., *see* Kaliszan, R., 512
Wainer, I. W., *see* Noctor, T. A. G., 506
Wainscott, D. B., *see* Kursar, J. D., 549
Walz, F. G., Jr., *see* Omiecinski, C. J., 249
Wang, C.-H. D., *see* Smith, K. E., 563
Wang, H., Regunathan, S., Meeley, M. P., and Reis, D. J. Isolation and characterization of imidazoline receptor protein from bovine adrenal chromaffin cells, 792
Wang, L.-H., *see* Benya, R. V., 1058
Wang, S.-Z., *see* Hu, J., 311
Wangoo, A., Haynes, A. R., Sutcliffe, S. P., Sorooshian, M., and Shaw, R. J. Modulation of platelet-derived growth factor B mRNA abundance in macrophages by colchicine and dibutyryl-cAMP, 584
Ward, A. M., *see* Kanetoshi, A., 1020
Warnholtz, A., *see* Eschenhagen, T., 773
Watson, S. P., *see* Varney, M. A., 671
Weber, W. W., *see* Martell, K. J., 265
Weinshank, R. L., *see* Smith, K. E., 563
Weinshank, R. L., *see* Zgombick, J. M., 180
Wells, J. N., *see* Sekhar, K. R., 103
West, J., *see* Duff, H. J., 570
Whitney, R. A., *see* Kimmitt, S. M., 307
Wieland, H. A., *see* Michel, M. C., 642
Wieland, T., and Jakobs, K. H. Evidence for nucleoside diphosphokinase-dependent channeling of guanosine 5'-(γ -thio)triphosphate to guanine nucleotide-binding proteins, 731

- Willard, J. M., *see* Ziegra, C. J., 203
Williams, H. L., *see* Felder, C. C., 838
Williams, K., Dichter, M. A., and Molinoff, P. B. Up-regulation of *N*-methyl-D-aspartate receptors on cultured cortical neurons after exposure to antagonists, 147
Williamson, J. R., *see* Mah, S. H., 217
Wilson, A., *see* Anantharam, V., 499
Wilson, A. L., Womble, S. W., Prakash, C., Cragoe, E. J., Jr., Blair, I. A., and Limbird, L. E. Novel amiloride analog allosterically modulates the α_2 -adrenergic receptor but does not inhibit Na⁺/H⁺ exchange, 175
Wojcik, W. J., *see* de Erausquin, G., 407
Wolfe, L., *see* Sekhar, K. R., 103
Wollheim, C. B., *see* Li, G., 489
Womble, S. W., *see* Wilson, A. L., 175
Wong, G., Sei, Y., and Skolnick, P. Stable expression of type I γ -aminobutyric acid/benzodiazepine receptors in a transfected cell line, 996
Wood, S. C., *see* Tonner, P. H., 890
Woodward, R. M., Polenzani, L., and Miledi, R. Characterization of bicuculline/baclofen-insensitive γ -aminobutyric acid receptors expressed in *Xenopus* oocytes. I. Effects of Cl⁻ channel inhibitors, 165
Wosnick, M. A., *see* Kamboj, R. K., 10
Woussen-Colle, M.-C., *see* Robberecht, P., 347
Wu, H. L., *see* Nambi, P., 336
Wu, K. K., *see* Ganousis, L. G., 1118
Wyse, B. M., *see* Kletzien, R. F., 558

X

- Xie, Y., Jones, G. S., Jr., and Loring, R. H. Effects of oxidizing and reducing analogs of acetylcholine on neuronal nicotinic receptors, 356

Y

- Yamada, H., *see* Kumagi, Y., 695
Yamada, K., *see* Imura, R., 964
Yamada, Y., *see* Rens-Domiano, 28
Yamamoto, N., Schols, D., De Clercq, E., Debyser, Z., Pauwels, R., Balzarini, J., Nakashima, H., Baba, M., Hosoya, M., Snoeck, R., Neyts, J., Andrei, G., Murrer, B. A., Theobald, B., Bossard, G., Henson, G., Abrams, M., and Picker, D. Mechanism of anti-human immunodeficiency virus action of polyoxometalates, a class of broad-spectrum antiviral agents, 1109
Yang, S.-G., *see* Hollenberg, M. D., 186
Yang-Feng, T., *see* Giros, B., 383
Yoshimura, H., *see* Kumagi, Y., 695
Yuan, J., *see* Baldessarini, R. J., 856

Z

- Zamel, D., *see* Israel, Y., 711
Zernig, G. Photoaffinity labeling of the partially purified mitochondrial phenylalkylamine calcium antagonist receptor, 1010
Zgombick, J. M., Schechter, L. E., Macchi, M., Hartig, P. R., Branchek, T. A., and Weinshank, R. L. Human gene S31 encodes the pharmacologically defined serotonin 5-hydroxytryptamine_{1B} receptor, 180
Zheng, K., *see* Giros, B., 383
Ziegra, C. J., Willard, J. M., and Oswald, R. E. Biochemical characterization of kainate receptors from goldfish brain, 203
Zimányi, I., Buck, E., Abramson, J. J., Mack, M. M., and Pessah, I. N. Ryanodine induces persistent inactivation of the Ca²⁺ release channel from skeletal muscle sarcoplasmic reticulum, 1049
Zimmerman, D. M., *see* Kamboj, R. K., 10
Zorumski, C. F., *see* Rodgers-Neame, N. T., 952
Zyglewska, T., *see* Ganousis, L. G., 1118
Zywulko, M., *see* Israel, Y., 711

SUBJECT INDEX FOR VOLUME 42

A

- A431 cells, activation of phospholipase C, epidermal growth factor, hepatocytes (rat), 743
- Acetaldehyde, -protein adducts, hypersensitivity (mouse), 711
- Acetylcholine, oxidizing and reducing analogs, neuronal nicotinic receptors, 356
- N*-Acetyltransferases, cloned (mouse), 265
- Adenosine, immunological identification of A₂ receptors, antipeptide antibody preparations, 391
- Adenylate cyclase
activation and receptor occupancy, pancreatic acinar cell membranes (rat), 347
stimulation of activity, opioid receptors, olfactory bulb (rat), 109
- Adenyl cyclase
guanine nucleotide-binding proteins and, supersensitive ventricles (guinea pig), 784
homologous 5-HT₄ receptor desensitization, colliculi neurons, 808
messenger systems, noscapine binding sites, brain (guinea pig), 619
pre-steady state study, β -adrenergic and purinergic receptors, C6 cell membranes, 1033
- Adipocytes
fatty acid-binding protein, regulation of gene expression, insulin-sensitizing agent (mouse), 558
white fat cell α_{1B} -adrenoceptors, characterization (rat), 403
- ADP-ribosylation, peptide inhibitors, pertussis toxin, trimeric GTP-binding proteins, 760
- Adrenal chromaffin cells, bovine, imidazoline receptor protein, 792
- Adrenoceptors
alpha-1, stimulation of inositol polyphosphates, heart (rat), 134
alpha-1B, characterization, white fat cells (rat), 403
alpha-2
allosteric modulation, novel amiloride analog, 175
cloning of two mouse genes, 16
pharmacological characteristics (human, rat, opossum), 1
turnover in brain, long term desipramine treatment (rat), 846
alpha-2 and *beta*-2, ADP-ribosylation, guanine nucleotide-binding protein, 6
beta
chemical and surgical sympathectomy, submandibular glands (rat), 971
growth of S49 lymphoma cells, epinephrine, 116
increases in cyclic AMP, human neuroblastoma cells, 753
pertussis toxin-sensitive guanine nucleotide-binding proteins, heart (rat), 773
beta-1 and *beta*-2, influence of age, liver (rat), 649
beta-3
functional properties, Chinese hamster ovary cells, 634
intron within protein-coding block (rodent, human), 964
- Aging, β_1 - and β_2 -adrenergic receptors, liver (rat), 649
- Albumin, human serum, stereochemical aspects, benzodiazepine binding, 506, 512
- Aldose reductase, mechanism of inhibition by menadione, 917
- Amiloride, novel analog, allosteric modulation, α_2 -adrenergic receptor, 175
- Amino acids
human dopamine transporter, cloning, pharmacological characterization (rat), 383
residues of 5-lipoxygenase-activating protein, binding, leukotriene biosynthesis inhibitors (human), 94
- γ -Aminobutyric acid, -gated chloride currents, benz[e]indene, postnatal rat hippocampal neurons, 952
- 1-Aminocyclopentyl-1,3-dicarboxylate, enantiomers, full antagonists of metabotropic glutamate receptors, phospholipase C (mouse), 322
- α -Amino-3-hydroxy-5-methyl-4-isoxazole propionate, receptor subtypes, complex pharmacological properties, 864
- Angiotensin-converting enzyme, two binding sites (rat), 286
- Angiotensin II
receptor antagonist radioligand, binding of L-158,809 (rat), 1077
receptors, phospholipase C- α , neuroblastoma NIE-115 cells (mouse), 217
- Antiarrhythmic agents, class I and IV, cytosolic calcium, cardiac sodium channel (rat), 570
- Anticonvulsant, -binding domain, phenytoin, voltage-dependent sodium channels, 1097
- Antidepressants, transgenic mouse model of endocrine changes, depression, 991
- Antifolates, determinants of cytotoxicity, cellular proliferation, development (rat), 687
- Antiinflammatory agents, synthesis of MCP-1/JE transcripts, human blood monocytes, 63
- Antimycotic agents, imidazole, transcriptional regulation, microsomal epoxide hydrolase gene (rat), 273
- Antiviral agents, anti-HIV action of polyoxometalates, mechanism of, 1109
- Aorta, atrial natriuretic peptide-induced relaxation, inhibition by HS-142-1 (rabbit), 982
- AP7, potency of NMDA receptor competitive antagonists, extracellular pH (mouse), 679
- Arachidonic acid
epoxygenases
identification, cytochromes P450 2C1 and 2C2 (rabbit), 958
immunochemical identity, embryo liver (chick), 1020
- Artery
coronary, relaxation, potent cGMP analogs (pig), 103
pulmonary, 8-hydroxy-2-(di-*n*-propylamino)tetralin response, 5-HT₄-like receptor, 817
- Arylamine *N*-acetyltransferases, hepatic, affinity alkylation (hamster), 82
- Ascorbic acid, acute intake, hydroxyl radical formation (rat), 723
- Atrial natriuretic peptide, -induced relaxation, inhibition by HS-142-1, aorta (rabbit), 982
- Autoantibodies, anti-liver microsomal, dihydralazine-induced hepatitis (rat), 280
- Autoradiography, chronic estradiol treatment, dopamine receptor reappearance in brain, irreversible blockade (rat), 480
- Aziridinylbenzoquinones, DT-diaphorase-mediated metabolism, DNA damage and cytotoxicity (human), 531

B

- Baclofen, -insensitive GABA receptors, *Xenopus* oocytes, 165
- Benz[e]indene, GABA-gated chloride currents, postnatal rat hippocampal neurons, 952
- Benzene, metabolites, cell-specific metabolism, bone marrow stroma (mouse), 1118

- Benzo(a)pyrene phenols, chrysene and, mono- and diglucuronide formation, UGT1A1 (rat), 613
- Benzodiazepine
- GABA_A receptors, functional interactions, imidazoquinoxaline derivatives (rat), 294
 - stereochemical aspects of binding, human serum albumin, 506, 512
- Betahistidine, increase in cytosolic Ca²⁺, histamine, dibutyl-cAMP-differentiated HL-60 cells, 227
- Bicuculline, baclofen-insensitive GABA receptors, *Xenopus* oocytes, 165
- Bleomycin hydrolase, neutralization, epitope-specific antibody, 57
- Bone marrow, stroma, cell-specific metabolism (mouse), 1118
- Brain
- agonist binding to somatostatin receptors, interaction, guanine nucleotide-binding regulatory proteins (rat), 398
 - biochemical characterization, kainate receptors (goldfish), 203
 - dopamine receptor reappearance, chronic estradiol treatment, autoradiography (rat), 480
 - haloperidol-sensitive σ_2 receptor, ionic zinc, function as endogenous ligand (rat), 471
 - high affinity taurine transporter, cloning and expression (rat), 563
 - 5-HT₂ receptors, unsurmountable antagonism, LSD and bromo-LSD, 826
 - noscapine binding sites (guinea pig), 619
 - striatal A_{2A} adenosine receptors, chemical modification, irreversible inhibition (rabbit), 123
 - turnover of α_2 -adrenoceptors, long term treatment, desipramine (rat), 846
- 2-Bromoethanamine, nephrotoxic lesions, nuclear magnetic resonance spectroscopy, pattern recognition analysis (rat), 922

C

- Calcium
- cytosolic
 - class I and IV antiarrhythmic drugs, sodium channel α subunit (rat), 570
 - histamine, dibutyl-cAMP-differentiated HL-60 cells, 227
 - intracellular, dual excitatory and inhibitory effects of opioids, NG108-15 cells, 1083
 - intraneuronal content, GABA_B receptors, cerebellar granule neurons (rat), 407
 - metabotropic glutamate receptors, inotropic glutamate responses, dorsal horn (rat), 192
 - mobilization, contractile and relaxant 5-HT receptors, intestinal muscle cells, 1090
 - mobilizing receptors, same guanine nucleotide-binding protein pool, hepatocytes (rat), 453
 - release channel, ryanodine-induced inactivation, skeletal muscle sarcoplasmic reticulum, 1049
- Calcium channel
- activator FPL 64176, characterization, GH₃ cells, 666
 - L-type, block by ω -agatoxin IIIA, 1,4-dihydropyridines, 947
 - T-type, preferential block by neuroleptics (rat, human), 364
 - voltage-gated, inhibition by KN-62, HIT cells, 489
- Calmodulin, inhibition of Ca²⁺ channels by KN-62, insulin secretion, HIT cells, 489
- Cannabinoid
- agonists, signal transduction pathways, transfected cells, 838
 - mediated immune modulation, cannabinoid receptor, spleen cells (mouse), 736
- Catecholamine, secretion from an adrenergic nerve trunk, axoplasmic transport, ouabain binding sites (cat), 141
- Cations, divalent, modulation of pentazocine binding, cerebellum (guinea pig), 882
- C cells, preferential block, T-type calcium channels, neuroleptics (rat, human), 364

- Cerebellar granule cells, block of glutamate toxicity, NMDA exposure (rat), 210
- Cerebellar granule neurons, intraneuronal ionized calcium content, GABA_B receptors (rat), 407
- Cerebellum, modulation of pentazocine binding, divalent cations (guinea pig), 882
- Cerebral cortex, inhibition of basal and agonist-stimulated responses, chronic lithium treatment, GH₃ cells, 671
- c-fos*, expression in human and murine multidrug-resistant cells, 69
- Chinese hamster ovary cells
- functional properties, *beta*-3 adrenoceptors, 634
 - kinetic properties, $\alpha_1\beta_1$ -GABA_A receptor channels, 872
- Chloride channel
- blocked conformation, binding kinetics, GABA_A receptor antagonists, 1069
 - inhibitors, bicuculline/baclofen-insensitive GABA receptors, *Xenopus* oocytes, 165
 - type I GABA_A/benzodiazepine receptors, stable expression, transfected cell line, 996
- Chloride current, GABA-gated, benz[e]indene, postnatal rat hippocampal neurons, 952
- Chrysene, benzo(a)pyrene phenols and, mono- and diglucuronide formation, UGT1A1 (rat), 613
- Cimetidine
- histamine H₂ receptor, theoretical studies, molecular mechanism of action, 373
 - increased cytosolic Ca²⁺, histamine, HL-60 promyelocytes, 235
- Colchicine, modulation, platelet-derived growth factor B mRNA (human), 584
- Copper, acute intake, hydroxyl radical formation (rat), 723
- Cyclic AMP
- cardiac, modulation of metabolism, adenosine receptor agonists and antagonists, 831
 - coexisting β_1 - and atypical β -adrenergic receptors, human neuroblastoma cells, 753
 - increased cytosolic Ca²⁺, histamine, HL-60 promyelocytes, 235
 - receptor-stimulated phosphoinositide hydrolysis, human neuroepithelioma cells, 340
 - tyrosine hydroxylase gene transcription rate, tyrosine hydroxylase mRNA stability, 898
- Cyclic GMP analogs, relaxation of coronary arteries (pig), 103
- Cyclodiene, binding kinetics, blocked chloride channel conformation, 1069
- Cysteine, residue, affinity alkylation, hepatic arylamine *N*-acetyltransferases (hamster), 82
- Cytochrome P-450
- arachidonic acid epoxigenases, immunochemical identity, chick embryo liver, 1020
 - isozymes, regiochemical differences, oxidation of methylenedioxy-phenyl groups (rabbit), 695
 - NMa/NMb/LM4, differential expression, olfactory mucosa and liver (rabbit), 1027
- Cytochrome P450 1A2, dihydralazine-induced hepatitis, anti-liver microsomal autoantibodies (rat), 280
- Cytochrome P450 2B2, null phenotype, deletion of structural gene (rat), 249
- Cytochrome P450 2C1, cytochrome P450 2C2 and, identification, arachidonic acid epoxigenases (rabbit), 958
- Cytochrome P450 2C11, microsomal, metabolite intermediate complexation, nortriptyline (rat), 931

D

- Deferoxamine, cellular pool of transient ferric iron, oxidative cell injury (rat), 703
- Deoxycytidine kinase, nucleotide specificity, 518
- Depression, endocrine changes, antidepressant drug action, transgenic mouse model, 991

- Desipramine, long term treatment, turnover of α_2 -adrenoceptors, brain (rat), 846
- Dibutyl-*c*-AMP, modulation, platelet-derived growth factor B mRNA (human), 584
- 2',3'-Dideoxyguanosine, metabolic pathways for activation, human lymphoid cells, 525
- 8-(*N,N*-Diethylamino)octyl-3,4,5-trimethoxybenzoate, cardiac muscarinic receptors, two allosteric modulators (rat), 638
- Dihydralazine, -induced hepatitis, anti-liver microsomal autoantibodies (rat), 280
- 1,4-Dihydropyridines, high affinity block of myocardial L-type calcium channels, spider toxin ω -agatoxin IIIA, 947
- Dioxin, response element, binding of human Ah receptor, *in vitro* transformation (rat), 603
- Diphenhydramine, increased cytosolic Ca^{2+} , histamine, HL-60 promyelocytes, 235
- Dithiane, binding kinetics, blocked chloride channel conformation, 1069
- Dithiobisacetylcholine, neuronal nicotinic receptors, 356
- DNA
 mechanism of anti-HIV virus action, polyoxometalates, 1109
 6-thioguanine incorporation, polymerase, ligase and endonuclease reactions, 802
- DNA, complementary
 liver minoxidil sulfotransferase (rat), 257
 rodent and human β_3 -adrenergic receptor genes, intron within protein-coding block (rodent, human), 964
- DNA damage, cytotoxicity and, DT-diaphorase-mediated metabolism, aziridinylbenzoquinones (human), 531
- DNA topoisomerase II, -mediated DNA cleavage, stimulation, ellipticine derivatives, 590
- Dopamine
 D2 guanine nucleotide-binding protein-coupled receptor, intrinsic activity determinations (rat), 432
 κ -opioid inhibition of release, ventral mesencephalic dissociated cell cultures (rat), 575
 prolonged D₂ antidopaminergic activity, spiperone derivatives, brain (rat), 856
 transporter, cloning, pharmacological characterization (rat), 383
- Dorsal horn, metabotropic glutamate receptors, ionotropic glutamate responses (rat), 192
- Doxorubicin, role of protein kinase C, modulation of multidrug resistance, 1004
- DT-diaphorase, -mediated metabolism, aziridinylbenzoquinones, DNA damage and cytotoxicity (human), 531
- E**
- Electron spin resonance, hydroxyl radical formation, acute copper and ascorbic acid intake (rat), 723
- Ellipticine, derivatives, stimulation, topoisomerase II-mediated DNA cleavage, 590
- Endonuclease, reactions, 6-thioguanine incorporation into DNA, 802
- Endothelin, receptor subtypes, kidney cortex, subtype-selective ligands (rat), 336
- Epidermal growth factor, activation of phospholipase C, hepatocytes (rat), 743
- Epinephrine, β -adrenergic receptor levels, growth, S49 lymphoma cells, 116
- Epitopes, -specific antibody, neutralization, bleomycin hydrolase, 57
- Epoxide hydrolase
 microsomal, gender-related expression, maturation (rat), 75
 transcriptional regulation of gene, imidazole antimycotic agents (rat), 273
- Epoxygenases
 arachidonic acid
 identification, cytochromes P450 2C1 and 2C2 (rabbit), 958
 immunochemical identity, embryo liver (chick), 1020
- Estradiol, brain dopamine receptor reappearance, after irreversible blockade, autoradiography (rat), 480
- Ethanol
 chronic administration, GABA_A receptor gene expression (rat), 415
 differential effects on electrical properties, various potassium channels, oocytes, 499
- F**
- Famotidine, increased cytosolic Ca^{2+} , histamine, HL-60 promyelocytes, 235
- Fatty acid, -binding protein, insulin-sensitizing agent, adipocytes (mouse), 558
- Ferritin, cellular pool of transient ferric iron, chelatable by deferoxamine, oxidative cell injury (rat), 703
- Ferrochelatase, hepatic, stereoselective inhibition, *N*-alkylated porphyrins (chick), 307
- Fibroblasts, BALB 3T3, transfection, neuromedin B receptors, 1058
- 5-Fluoro-2'-deoxyuridine, resistance in mammalian and bacterial cells, histidine replacement, human thymidylate synthase, 242
- Folypolyglutamate synthetase, determinants of antifolate cytotoxicity, cellular proliferation, development (rat), 687
- N*-Formyl-L-methionyl-L-leucyl-L-phenylalanine, increase in cytosolic Ca^{2+} , histamine, dibutyl-*c*-AMP-differentiated HL-60 cells, 227
- 10-Formyltetrahydrofolate, 5,10-methylenetetrahydrofolate and, depletion by methotrexate, hepatoma cells, 909
- FPL 64176, characterization in GH₃ cells, 666
- G**
- Gallamine, cardiac muscarinic receptors, two allosteric modulators (rat), 638
- Gene
 adipocyte fatty acid-binding protein, insulin-sensitizing agent (mouse), 558
 α_2 -adrenergic receptor subtypes, mouse α_2 -C10 homolog, interspecies variation in antagonist binding, 16
 deletion, null phenotype, cytochrome P450 2B2 (rat), 249
 GABA_A receptor, chronic ethanol administration (rat), 415
 glucocorticoid receptor, antidepressant drug action, endocrine changes in depression, 991
 microsomal epoxide hydrolase, gender-related expression, maturation (rat), 75
 Nat-1 and *Nat-2*, cloned *N*-acetyltransferases (mouse), 265
 rodent and human β_3 -adrenergic receptor, intron within protein-coding block, 964
 S31, serotonin 5-HT_{1E} receptor (human), 180
 synthesis of MCP-1/JE transcripts, antiinflammatory agents, human blood monocytes, 63
- GH₃ cells
 characterization of FPL 64176, 666
 inhibition of basal and agonist-stimulated responses, chronic lithium treatment, 671
- Glioma, hybrid NG108-15 cells, dual excitatory and inhibitory effects of opioids, intracellular calcium, 1083
- Glucocorticoid, tyrosine hydroxylase gene transcription rate, tyrosine hydroxylase mRNA stability, 898
- Glutamate, block of toxicity by NMDA exposure, cerebellar granule cells (rat), 210
- G proteins
 adenosine receptor agonists and antagonists, modulation, cardiac cyclic AMP, 831
 adenylyl cyclase and, supersensitive ventricles (guinea pig), 784
 ADP-ribosylation, β_2 - and α_2 -adrenergic receptors, 6
 β -adrenergic receptors and, chemical and surgical sympathectomy, submandibular glands (rat), 971
 agonist binding to brain somatostatin receptors (rat), 398
 dopamine D2-coupled receptor, intrinsic activity determinations (rat), 432

- increase in cytosolic Ca^{2+} , histamine, dibutyl-cAMP-differentiated HL-60 cells, 227
- molecular pharmacological differences, interaction of serotonin, 5-HT_{1C} and 5-HT₂, 328
- neuromedin B receptors, transfection into BALB 3T3 fibroblasts, 1058
- nucleoside diphosphokinase-dependent channeling, guanosine 5'-(γ -thio)triphosphate, 731
- pertussis toxin-sensitive, β -adrenoceptor-mediated up-regulation (rat), 773
- same guanine nucleotide-binding protein pool, different calcium-mobilizing receptors, hepatocytes (rat), 453
- GTP-binding proteins, trimeric, peptide inhibitors of ADP-ribosylation, pertussis toxin, 760
- Guanine nucleotides, indirect effect on antagonist binding, A₁ adenosine receptors, 765
- Guanosine 5'-(γ -thio)triphosphate, nucleoside diphosphokinase-dependent channeling, guanine nucleotide-binding proteins, 731
- ## H
- Haloperidol, -sensitive σ_2 receptor in brain, ionic zinc, function as endogenous ligand (rat), 471
- Heart
- α_1 -adrenergic stimulation, inositol polyphosphates (rat), 134
 - allosteric modulation of muscarinic receptors, endogenous ligands (rat), 311
 - class I and IV antiarrhythmic drugs, cytosolic calcium, sodium channel α subunit (rat), 570
 - cyclic AMP metabolism, modulation, adenosine receptor agonists and antagonists, 831
 - L-type calcium channels, block by ω -agatoxin IIIA, 1,4-dihydropyridines, 947
 - muscarinic receptors, two allosteric modulators (rat), 638
 - pertussis toxin-sensitive guanine nucleotide-binding proteins, β -adrenoceptor-mediated up-regulation (rat), 773
- HELA S3 cells, cell-protecting effect, herpes simplex virus-1, 9-(2-phosphonylmethoxyethyl)adenine, 537
- Hepatitis, dihydralazine-induced, anti-liver microsomal autoantibodies (rat), 280
- Hepatocytes
- activation of phospholipase C, epidermal growth factor (rat), 743
 - same guanine nucleotide-binding protein pool, different calcium-mobilizing receptors (rat), 453
- Hepatoma, depletion of 5,10-methylenetetrahydrofolate, 10-formyltetrahydrofolate, methotrexate, 909
- Herpes simplex virus-1, cell-protecting effect, 9-(2-phosphonylmethoxyethyl)adenine, HELA S3 cells, 537
- High performance liquid chromatography, stereochemical aspects, benzodiazepine binding, human serum albumin, 506, 512
- Hippocampus, neurons, effect of benz[e]indene, GABA-gated chloride currents, 952
- Histamine
- cytosolic Ca^{2+} in HL-60 promyelocytes, H₂ receptors, 235
 - increase in cytosolic Ca^{2+} , dibutyl-cAMP-differentiated HL-60 cells, 227
- HL-60 cells
- dibutyl-cAMP-differentiated, increase in cytosolic Ca^{2+} , histamine, 227
 - promyelocytes, increase in cytosolic Ca^{2+} , histamine, 235
- HS-142-1, inhibition of atrial natriuretic peptide-induced relaxation, aorta (rabbit), 982
- HT29 cells, α_2 -adrenergic receptors, pharmacological characteristics (human, rat, opossum), 1
- Human immunodeficiency virus, anti-HIV action of polyoxometalates, 1109
- 8-Hydroxy-2-(di-*n*-propylamino)tetralin, -responsive 5-HT₄-like receptor, bovine pulmonary artery smooth muscle cells, 817
- ω -Hydroxylase, arachidonic acid epoxygenases, immunochemical identity, chick embryo liver, 1020
- Hydroxyl radical, formation, acute copper and ascorbic acid intake (rat), 723
- Hypersensitivity, acetaldehyde-protein adducts (mouse), 711
- Hypothalamic-pituitary-adrenal axis, endocrine changes, antidepressant drug action, transgenic mouse model, 991
- ## I
- ICI174864, antagonist-induced transient down-regulation, δ -opioid receptors, NG108-15 cells, 445
- Imidazole
- antimycotic agents, transcriptional regulation, microsomal epoxide hydrolase gene (rat), 273
 - derivatives, rate constant of singlet oxygen quenching, anti-inflammatory activity (rat), 718
- Imidazoline, receptor protein characterization, bovine adrenal chromaffin cells, 792
- Imidazoquinoxaline, derivatives, functional interactions, benzodiazepine-GABA_A receptors (rat), 294
- Immunoglobulin E, hypersensitivity, acetaldehyde-protein adducts (mouse), 711
- Impromidine, increased cytosolic Ca^{2+} , histamine, HL-60 promyelocytes, 235
- Indoleamines, nescapine binding sites in brain (guinea pig), 619
- Inositol polyphosphates, α_1 -adrenergic stimulation, heart (rat), 134
- Insecticides, binding kinetics of GABA_A receptor antagonists, blocked chloride channel conformation, 1069
- Insulin
- secretion, inhibition of Ca^{2+} channels by KN-62, HIT cells, 489
 - sensitizing agent, adipocyte fatty acid-binding protein (mouse), 558
- Intestine, muscle cells, contractile and relaxant 5-HT receptors, Ca^{2+} mobilization, 1090
- Iron, ferric, chelatable by deferoxamine, oxidative cell injury (rat), 703
- ## K
- Kainate
- molecular structure of humEAA2, 10
 - receptors, biochemical characterization, brain (goldfish), 203
- Kidney
- cortex, endothelin receptor subtypes (rat), 336
 - opossum cells, regulation of 5-HT_{1B} receptor, exposure to agonists, 464
- KN-62, inhibition of voltage-gated Ca^{2+} channels, insulin secretion, HIT cells, 489
- ## L
- L-158,809, characterization of binding (rat), 1077
- L-703,606, binding to neurokinin-1 receptor, 458
- Leukotrienes
- biosynthesis inhibitors, amino acid residues, 5-lipoxygenase-activating protein (human), 94
 - 5-lipoxygenase-activating protein, cross-species comparison (human, monkey, horse, pig, cow, sheep, rabbit, dog, rat, mouse), 1014
- Ligands
- binding to 5-HT₂ and 5-HT_{1C} receptors, receptor domains, 627
 - endogenous, allosteric modulation, cardiac muscarinic receptors (rat), 311
- Ligase, 6-thioguanine incorporation into DNA, 802
- Liposomes, interactions of salmeterol with membrane bilayers, equilibrium and kinetic studies, 596
- 5-Lipoxygenase
- activating protein
 - amino acid residues, leukotriene biosynthesis inhibitors (human), 94
 - cross-species comparison (human, monkey, horse, pig, cow, sheep, rabbit, dog, rat, mouse), 1014

Lithium, inhibition of basal and agonist-stimulated responses, cerebral cortex and GH₃ cells, 671

Liver

- arylamine *N*-acetyltransferases, affinity alkylation (hamster), 82
- chick embryo, immunochemical identity, arachidonic acid epoxigenases, 1020
- ferrochelatase, stereoselective inhibition, *N*-alkylated porphyrins (chick), 307
- immunological identification, A₂ adenosine receptors, antipeptide antibody preparations, 391
- influence of age, β_1 - and β_2 -adrenergic receptors (rat), 649
- mechanism for modulation of activity, NAD(P)H:quinone acceptor oxidoreductase, menadione (rat), 545
- 3-methylcholanthrene-inducible phenol UDP-glucuronosyltransferase, mono- and diglucuronide formation, chrysene and benzo(a)pyrene phenols (rat), 613
- microsomal autoantibodies, dihydralazine-induced hepatitis (rat), 280
- minoxidil sulfotransferase, expression of cDNA (rat), 257
- olfactory mucosa and, differential expression, cytochrome P450 NMa/NMb/LM4 (rabbit), 1027
- oxidation of methylenedioxyphenyl groups, regiochemical differences, cytochrome P450 isozymes (rabbit), 695

Liver microsomes

- cytochrome P450 2C11, metabolite intermediate complexation, nortriptyline (rat), 931
- epoxide hydrolase, gender-related expression, maturation (rat), 75
- epoxide hydrolase gene, transcriptional regulation, imidazole antimycotic agents (rat), 273

Lung, α_2 -adrenergic receptors, pharmacological characteristics (human, rat, opossum), 1

LY 257883, potency of NMDA receptor competitive antagonists, extracellular pH (mouse), 679

Lymphoid cells, metabolic pathways for activation, 2',3'-dideoxyguanosine (human), 525

Lymphoma, growth of S49 cells, β -adrenergic receptor levels, epinephrine, 116

Lysergic acid diethylamine, bromo-LSD and, unsurmountable antagonism, brain 5-HT₂ receptors, 826

M

Menadione

- mechanism for modulation of activity, NAD(P)H:quinone acceptor oxidoreductase, liver (rat), 545
- mechanism of inhibition of aldose reductase, 917

Mercury(II) chloride, nephrotoxic lesions, nuclear magnetic resonance spectroscopy, pattern recognition analysis (rat), 922

Methotrexate, depletion of 5,10-methylenetetrahydrofolate, cultured hepatoma cells, 909

N-Methyl-D-aspartate, exposure, block of glutamate toxicity, cerebellar granule cells (rat), 210

3-Methylcholanthrene, -inducible phenol UDP-glucuronosyltransferase, mono- and diglucuronide formation, chrysene and benzo(a)pyrene phenols (rat), 613

Methylenedioxyphenyl, oxidation by liver, regiochemical differences, cytochrome P450 isozymes (rabbit), 695

5,10-Methylenetetrahydrofolate, 10-formyltetrahydrofolate and, depletion by methotrexate, hepatoma cells, 909

Minoxidil sulfotransferase, liver, expression of cDNA (rat), 257

Mitochondria, phenylalkylamine calcium antagonist receptor, photoaffinity labeling, 1010

MK-801, up-regulation of NMDA receptors, cortical neurons (rat), 147

Monocytes, human blood, synthesis of MCP-1/JE transcripts, antiinflammatory agents, 63

Mucosa, olfactory, differential expression, cytochromes P450 NMa/NMb/LM4 (rabbit), 1027

Multidrug resistance

- human and murine cells, *c-fos* expression, 69
- modulation, role of protein kinase C, doxorubicin, 1004

Muscle, intestinal, contractile and relaxant 5-HT receptors, Ca²⁺ mobilization, 1090

Muscle, skeletal, sarcoplasmic reticulum, ryanodine-induced inactivation, Ca²⁺ release channel, 1049

Muscle, smooth

- bovine pulmonary artery, 8-hydroxy-2-(di-*n*-propylamino)tetralin response, 5-HT₄ receptor, 817
- gastric, thrombin receptor polypeptide (guinea pig), 186
- relaxation of coronary arteries, cGMP analogs (pig), 103

N

Na⁺/Ca²⁺ exchange, axoplasmic transport of ouabain binding sites, catecholamine secretion, adrenergic nerve trunk (cat), 141

NAD(P)H:quinone acceptor oxidoreductase, mechanism for modulation of activity, menadione, liver (rat), 545

Na⁺/H⁺ exchange, allosteric modulation of α_2 -adrenergic receptor, novel amiloride analog, 175

Naloxone, antagonist-induced transient down-regulation, δ -opioid receptors, NG108-15 cells, 445

Naltrexone, antagonist-induced transient down-regulation, δ -opioid receptors, NG108-15 cells, 445

β -Naphthoflavone, -induced cytochrome P-450 arachidonic acid epoxigenases, immunochemical identity, chick embryo liver, 1020

Nerve, hypogastric, axoplasmic transport, ouabain binding sites (cat), 141

Neural crest, preferential block, T-type calcium channels, neuroleptics (rat, human), 364

Neurite, staurosporine-induced outgrowth, protein kinase C inhibition, PC12 cells, 35

Neuroblastoma

- coexisting β_1 - and atypical β -adrenergic receptors, increases in cyclic AMP, 753

hybrid NG108-15 cells, dual excitatory and inhibitory effects of opioids, intracellular calcium, 1083

interaction of pumiliotoxin B, "alkaloid-binding domain", voltage-dependent sodium channel, 1104

NIE-115 cells, solubilized angiotensin II receptors, phospholipase C- α (mouse), 217

Neuroepithelioma cells, receptor-stimulated phosphoinositide hydrolysis, potentiation by cyclic AMP (human), 340

Neurokinin-1, receptor binding, L-703606, 458

Neuroleptics, preferential block of T-type calcium channels (rat, human), 364

Neuromedin B, receptors, transfection into BALB 3T3 fibroblasts, 1058

Neurons

- colliculi, desensitization, homologous 5-HT₄ receptor, 808

cortical, up-regulation, NMDA receptors (rat), 147

hippocampal, effect of benz[e]indene, GABA-gated chloride currents, 952

hypothalamic GT1-7, functional GABA_A receptors, 197

ventral mesencephalic dissociated cell cultures, κ -opioid inhibition, dopamine release (rat), 575

Neuropeptide Y, receptor subtypes, centrally truncated analogs, characterization, 642

Neurotoxicology, molecular, trimethyltin, 44

Neurotransmitters, human dopamine transporter, cloning, pharmacological characterization (rat), 383

NG108-15 cells

- antagonist-induced transient down-regulation, δ -opioid receptors, 445

dual excitatory and inhibitory effects, opioids, intracellular calcium, 1083

protein kinase C activation, agonist-induced δ -opioid receptor down-regulation, 656

Nicotine, self-inhibition, low efficacy at nicotinic acetylcholine receptor, *Torpedo*, 890

Nortriptyline, metabolite intermediate complexation, microsomal cytochrome P450 2C11 (rat), 931

Noscapine, binding sites in brain (guinea pig), 619
 Nuclear magnetic resonance spectroscopy, pattern recognition analysis and, mercury(II) chloride and 2-bromoethanamine, nephrotoxic lesions (rat), 922
 Nucleoside diphosphokinase, -dependent channeling, guanosine 5'-(γ -thio)triphosphate, guanine nucleotide-binding proteins, 731
 Nucleotide, specificity of human deoxycytidine kinase, 518

O

Obidoxime, cardiac muscarinic receptors, two allosteric modulators (rat), 638
 Olfaction, mucosa and liver, differential expression, cytochromes P450 NMa/NMb/LM4 (rabbit), 1027
 Olfactory bulb, stimulation of adenylate cyclase activity, opioid receptors (rat), 109
 Oocytes
 differential effects of ethanol, electrical properties, various potassium channels, 499
 Xenopus
 bicuculline/baclofen-insensitive GABA receptors, 165
 tunicamycin, desensitization of acetylcholine receptors, 152
 Opioid
 dual excitatory and inhibitory effects, intracellular calcium, hybrid NG108-15 cells, 1083
 kappa, inhibition of dopamine release, ventral mesencephalic dissociated cell cultures (rat), 575
 Ornithine decarboxylase, suppression and polyamine depletion, anti-proliferative activity, polyamine analogs, 302
 Ouabain, binding sites, axoplasmic transport, catecholamine secretion from an adrenergic nerve trunk (cat), 141
 Oxygen, singlet, quenching by imidazole derivatives, anti-inflammatory activity (rat), 718

P

Pancreas, acinar cell membranes, receptor occupancy, adenylate cyclase activation (rat), 347
 PC12 cells, staurosporine-induced neurite outgrowth, independence, protein kinase C inhibition, 35
 Pentazocine, modulation of binding to cerebellum, divalent cations (guinea pig), 882
 Pentobarbital, kinetic properties in Chinese hamster ovary cells, $\alpha_1\beta_1$ -GABA_A receptor channels, 872
 Pertussis toxin
 peptide inhibitors of ADP-ribosylation, trimeric GTP-binding proteins, 760
 -sensitive guanine nucleotide-binding proteins, β -adrenoceptor-mediated up-regulation, heart (rat), 773
 P-glycoprotein, human and murine multidrug-resistant cells, *c-fos* expression, 69
 pH, extracellular, potency of NMDA receptor competitive antagonists (mouse), 679
 Phenobarbital, arachidonic acid epoxigenases, immunochemical identity, chick embryo liver, 1020
 Phenol sulfotransferases, liver minoxidil sulfotransferase, expression of cDNA (rat), 257
 Phenothiazine, derivatives, gate-dependent blockade, sodium channels (frog), 423
 Phenylalkylamine, calcium antagonist receptor, photoaffinity labeling, mitochondria, 1010
 Phenytoin, novel anticonvulsant-binding domain, voltage-dependent sodium channels, 1097
 Phosphoinositide
 noscapine binding sites in brain (guinea pig), 619
 receptor-stimulated hydrolysis, potentiation by cyclic AMP, human neuroepithelioma cells, 340
 Phospholipase C
 activation by epidermal growth factor, hepatocytes (rat), 743

1-aminocyclopentyl-1,3-dicarboxylate enantiomers, full agonists, metabotropic glutamate receptors (mouse), 322
 increase in cytosolic Ca²⁺
 histamine, dibutyryl-cAMP-differentiated HL-60 cells, 227
 histamine, HL-60 promyelocytes, 235
 Phospholipase C- α , solubilized angiotensin II receptors, neuroblastoma NIE-115 cells (mouse), 217
 9-(2-Phosphonylmethoxyethyl)adenine, cell-protecting effect, herpes simplex virus-1, HELA S3 cells, 537
 Photoaffinity labeling, mitochondrial phenylalkylamine calcium antagonist receptor, 1010
 Picrotoxin, kinetic properties in Chinese hamster ovary cells, $\alpha_1\beta_1$ -GABA_A receptor channels, 872
 Pituitary, somatostatin receptor, preferential expression, affinity for somatostatin-28, 939
 Platelet-derived growth factor B, messenger RNA, modulation, colchicine and dibutyryl-cAMP (human), 584
 Platelets, pre-steady state study, β -adrenergic and purinergic receptors, C6 cell membranes, 1033
 Polyamines
 depletion, ornithine decarboxylase suppression, polyamine analogs, 302
 spermine, voltage-dependent reduction, NMDA receptor single-channel conductance (rat), 157
 Polymerase, 6-thioguanine incorporation into DNA, 802
 Polyoxometalates, anti-HIV action, mechanism of, 1109
 Polyphosphoinositide, muscarinic m3 receptor-stimulated responses, rapid desensitization, 1042
 Porphyrins, *N*-alkylated, stereoselective inhibition, hepatic ferrochelatase (chick), 307
 Potassium channel, differential effects of ethanol, electrical properties, oocytes, 499
 Protamine, allosteric modulation of muscarinic receptors, endogenous ligands, heart (rat), 311
 Protein kinase, relaxation of coronary arteries, cGMP analogs (pig), 103
 Protein kinase C
 activation, agonist-induced δ -opioid receptor down-regulation, NG108-15 cells, 656
 inhibition, staurosporine-induced neurite outgrowth, PC12 cells, 35
 modulation of multidrug resistance, doxorubicin, 1004
 Protein kinase II, inhibition of Ca²⁺ channels by KN-62, insulin secretion, HIT cells, 489
 Pumiliotoxin B, interaction with "alkaloid-binding domain", voltage-dependent sodium channel, 1104

R

Radioligands, angiotensin II receptor antagonist, binding of L-158,809 (rat), 1077
 Rat1hER cells, activation of phospholipase C, epidermal growth factor, hepatocytes (rat), 743
 Receptors
 σ_2 , ionic zinc, function as endogenous ligand (rat), 471
 acetylcholine, desensitization, tunicamycin, 152
 adenosine, agonists and antagonists, modulation of cardiac cyclic AMP metabolism, 831
 adenosine A₁, antagonist binding, indirect effect of guanine nucleotides, 765
 adenosine A₂, immunological identification, antipeptide antibody preparations, 391
 adenosine A_{2a}, chemical modification, irreversible inhibition (rabbit), 123
 β -adrenergic and purinergic, pre-steady state study, C6 cell membranes, 1033
 Ah, binding to dioxin response element, *in vitro* transformation, 603
 α -amino-3-hydroxy-5-methyl-4-isoxazole propionate, complex pharmacological properties, 864
 angiotensin II

Receptors—continued

- antagonist radioligand, binding of L-158,809 (rat), 1077
- phospholipase C- α , neuroblastoma NIE-115 cells (mouse), 217
- calcium-mobilizing, same guanine nucleotide-binding protein pool, hepatocytes (rat), 453
- cannabinoid
 - agonists, signal transduction pathways, 838
 - immune modulation, spleen cells (mouse), 736
- domains, ligand binding to 5-HT₂ and 5-HT_{1C} receptors, 627
- dopamine D₂, spiperone derivatives, brain (rat), 856
- endothelin, subtypes in kidney cortex, subtype-selective ligands (rat), 336
- GABA, bicuculline/baclofen insensitivity, *Xenopus* oocytes, 165
- GABA_A
 - benzodiazepine, imidazoquinoxaline derivatives (rat), 294
 - gene expression, chronic ethanol administration (rat), 415
 - immortalized hypothalamic GT1-7 neurons, 197
 - noncompetitive antagonists, binding kinetics, 1069
- GABA_A $\alpha_1\beta_1$, kinetic properties, Chinese hamster ovary cells, 872
- GABA_B, intraneuronal ionized calcium content, cerebellar granule neurons (rat), 407
- glucocorticoid, antidepressant drug action, endocrine changes in depression, 991
- glutamate
 - 1-aminocyclopentyl-1,3-dicarboxylate enantiomers, phospholipase C (mouse), 322
 - inotropic glutamate responses, dorsal horn (rat), 192
- guanylyl cyclase-linked, atrial natriuretic peptide-induced relaxation, inhibition by HS-142-1 (rabbit), 982
- histamine H₁, cytosolic Ca²⁺, dibutyryl-cAMP-differentiated HL-60 cells, 227
- histamine H₂
 - increased cytosolic Ca²⁺, HL-60 promyelocytes, 235
 - theoretical studies, antagonists, 373
- 5-HT, contractile and relaxant properties, intestinal muscle cells, 1090
- 5-HT_{1B}, regulation after exposure to agonists, opossum kidney cells, 464
- 5-HT_{1C} and 5-HT₂, interaction of serotonin, molecular pharmacological differences, 328
- 5-HT_{1D}, cloning and pharmacological characterization, 439
- 5-HT_{1E}, human gene S31, 180
- 5-HT₂, unsurmountable antagonism, LSD and bromo-LSD, 862
- 5-HT_{2F}, molecular cloning, stomach fundus (rat), 549
- 5-HT₄
 - desensitization, colliculi neurons, 808
 - 8-hydroxy-2-(di-*n*-propylamino)tetralin response, bovine pulmonary artery smooth muscle cells, 817
- imidazoline, protein, bovine adrenal chromaffin cells, 792
- kainate
 - biochemical characterization, brain (goldfish), 203
 - humEAA2, molecular structure, 10
- N*-methyl-D-aspartate
 - single-channel conductance, spermine (rat), 157
 - up-regulation, cortical neurons (rat), 147
- N*-methyl-D-aspartic acid, competitive antagonists, extracellular pH and potency (mouse), 679
- muscarinic
 - allosteric modulation by protamine, heart (rat), 311
 - two allosteric modulators, heart (rat), 638
- muscarinic m3, rapid desensitization, polyphosphoinositide responses, 1042
- neurokinin-1, L-703606 binding, 458
- neuromedin B, transfection into BALB 3T3 fibroblasts, 1058
- neuropeptide Y, characterization, centrally truncated analogs, 642
- nicotinic, oxidizing and reducing analogs, acetylcholine, 356
- nicotinic acetylcholine, low efficacy and nicotine self-inhibition, *Torpedo*, 890

- occupancy and adenylate cyclase activation, pancreatic acinar cell membranes (rat), 347
- opioid, stimulation of adenylate cyclase activity, olfactory bulb (rat), 109
- opioid *delta*
 - agonist-induced down-regulation, protein kinase C activation, 656
 - antagonist-induced transient down-regulation, NG108-15 cells, 445
- opioid *kappa*, inhibition of dopamine release, ventral mesencephalic dissociated cell cultures (rat), 575
- phenylalkylamine calcium antagonist, photoaffinity labeling, mitochondria, 1010
- somatostatin
 - affinity for somatostatin-28, pituitary, 939
 - agonist binding, brain (rat), 398
 - pharmacological properties, 28
 - stimulated phosphoinositide hydrolysis, cyclic AMP, human neuroepithelioma cells, 340
- thrombin, action of polypeptide, gastric smooth muscle (guinea pig), 186
- type I GABA_A/benzodiazepine, stable expression, transfected cell line, 996
- Retina, neuronal nicotinic receptors, oxidizing and reducing analogs, acetylcholine, 356
- RNA, mechanism of anti-HIV virus action, polyoxometalates, 1109
- RNA, messenger
 - GABA_A receptor gene expression, chronic ethanol administration (rat), 415
 - microsomal epoxide hydrolase, gender-related expression, maturation (rat), 75
 - pertussis toxin-sensitive G proteins, β -adrenoceptor-mediated up-regulation (rat), 773
 - platelet-derived growth factor B, modulation, colchicine and dibutyryl-cAMP (human), 584
 - transcriptional regulation, microsomal epoxide hydrolase gene, imidazole antimycotic agents (rat), 273
 - tyrosine hydroxylase, regulation, cyclic AMP and glucocorticoid, 898
- Ryanodine, persistent inactivation of Ca²⁺ release channel, skeletal muscle sarcoplasmic reticulum, 1049

S

- Salmeterol, interactions with membrane bilayers, equilibrium and kinetic studies, 596
- Sarcoplasmic reticulum, skeletal muscle, ryanodine-induced inactivation, Ca²⁺ release channel, 1049
- Serotonin
 - interaction with 5-HT_{1C} and 5-HT₂ receptors, molecular pharmacological differences, 328
 - ligand binding, 5-HT₂ and 5-HT_{1C} receptors, receptor domains, 627
 - novel 5-HT_{2F} receptor, molecular cloning, stomach fundus (rat), 549
 - novel human 5-HT_{1D} receptor subtype, cloning and pharmacological characterization, 439
 - regulation of 5-HT_{1B} receptor, exposure to agonists, kidney opossum cells, 464
- SK&F 96365, increased cytosolic Ca²⁺, histamine, HL-60 promyelocytes, 235
- Sodium channel
 - gate-dependent blockade, phenothiazine derivatives (frog), 423
 - α subunit, class I and IV antiarrhythmic drugs, cytosolic calcium (rat), 570
 - voltage-dependent
 - interaction of pumiliotoxin B, "alkaloid-binding domain", 1104
 - novel anticonvulsant-binding domain, phenytoin, 1097
- Somatostatin, receptors, pharmacological properties, 28
- Somatostatin-28, pituitary somatostatin receptor, molecular cloning and expression, 939
- Spermine, voltage-dependent reduction, NMDA receptor single-channel conductance (rat), 157

Spider toxin, ω -agatoxin IIIA, high affinity block, L-type calcium channels, 947
 Spinal cord, metabotropic glutamate receptors, inotropic glutamate responses, dorsal horn (rat), 192
 Spiperone, alkylating and nonalkylating derivatives, prolonged D₂ antiodopaminergic activity, brain (rat), 856
 Spleen, cannabinoid-mediated immune modulation, cannabinoid receptor (mouse), 736
 Stannin, molecular neurotoxicology of trimethyltin, 44
 Staurosporine, -induced neurite outgrowth in PC12 cells, independence, protein kinase C inhibition, 35
 Stomach fundus, novel serotonin receptor, molecular cloning, characterization (rat), 549
 Stroma, bone marrow, cell-specific metabolism (mouse), 1118
 Submandibular glands, chemical and surgical sympathectomy, β -adrenergic receptor and G proteins (rat), 971
 Sympathectomy, chemical and surgical, β -adrenergic receptors and G proteins, submandibular glands (rat), 971
 Synaptoneurosomes, interaction of pumiliotoxin B, "alkaloid-binding domain", voltage-dependent sodium channel, 1104

T

Tachykinins, L-703606 binding, neurokinin-1 receptor, 458
 Taurine, high affinity transporter, cloning and expression, brain (rat), 563
 2,3,7,8-Tetrachlorodibenzo-*p*-dioxin
 binding of human Ah receptor, *in vitro* transformation (rat), 603
 -induced cytochrome P-450 arachidonic acid epoxigenases, immunochemical identity, chick embryo liver, 1020
 Tetrahydroaminoacridine, cardiac muscarinic receptors, two allosteric modulators (rat), 638
 Tetrahydrocannabinoid, cannabinoid agonists, signal transduction pathways, cannabinoid receptor clones, 838
 6-Thioguanine, incorporation into DNA, polymerase, ligase and endonuclease reactions, 802

Thiols, ryanodine-induced inactivation, Ca²⁺ release channel, skeletal muscle sarcoplasmic reticulum, 1049
 Thrombin, receptor polypeptide, gastric smooth muscle (guinea pig), 186
 Thymidylate synthase, resistance to 5-fluoro-2'-deoxyuridine, histidine replacement, mammalian and bacterial cells, 242
 Tiotidine, histamine H₂ receptor, theoretical studies, molecular mechanism of action, 373
Torpedo, nicotine self-inhibition, low efficacy, nicotinic acetylcholine receptor, 890
 Trimethyltin, molecular neurotoxicology, 44
 Trioxabicyclooctane, binding kinetics, blocked chloride channel conformation, 1069
 Tunicamycin, desensitization of acetylcholine receptors, *Xenopus* oocytes, 152
 Tyrosine, resistance to 5-fluoro-2'-deoxyuridine, histidine replacement, human thymidylate synthase, 242
 Tyrosine hydroxylase, gene transcription rate and mRNA stability, regulation, cyclic AMP and glucocorticoid, 898

V

Ventricles, supersensitive, adenylyl cyclase, guanine nucleotide-binding proteins (guinea pig), 784
 Vitamin K3, mechanism of inhibition of aldose reductase, 917
 Voltage
 -dependent sodium channel
 interaction of pumiliotoxin B, "alkaloid-binding domain", 1104
 phenytoin, anticonvulsant-binding domain, 1097

W

White fat cells, α_{1B} -adrenoceptors, characterization (rat), 403

Z

Zinc, ionic, function as endogenous ligand, haloperidol-sensitive σ_2 receptor in brain (rat), 471

Newsworthy and timely
articles in your field


MOLECULAR PHARMACOLOGY

Editor: **T. Kendall Harden, PhD**, University of North Carolina
School of Medicine, Chapel Hill, North Carolina

Is your special interest receptors and neurotransmitters... drug
metabolism... antibiotic and anticancer drug actions... or other
areas related to the molecular basis of drug action? If so, you
should be subscribing to **MOLECULAR PHARMACOLOGY**.

The editor's and editorial board's high standards ensure that the
papers you read in **MOLECULAR PHARMACOLOGY** are on the
cutting edge of research on drug action and selective toxicity at the
molecular level. Original applications of biochemistry, biophysics,
genetics, and molecular biology are juxtaposed with innovative
pharmacologic research to elucidate basic problems in pharma-
cology and toxicology, including such areas as molecular mecha-
nisms involved in drug receptor-effector coupling, xenobiotic
metabolism, and antibiotic and anticancer drug action. Start your
subscription today to ensure access to the most newsworthy papers
in your field. **Monthly**

Call toll-free to start your subscription immediately, **1-800-638-6423**
from anywhere in the U.S. or Canada.



YES! Enter my subscription:

Avoid future rate increases and ensure uninterrupted service—enter
your multiyear subscription today!

Molecular Pharmacology (monthly)

☐ Individual: \$105/yr ☐ Institutions: \$230/yr
(Please add \$30.00 outside the U.S.; in Canada, also add 7% GST.)
☐ New Subscription ☐ Renewal ☐ 3 yrs ☐ 2 yrs ☐ 1 yr

name _____

address _____

city state zip _____

Payment options:

☐ Check enclosed ☐ Bill me
☐ VISA ☐ MasterCard ☐ American Express

card # _____

signature/P.O.# _____

CA, MD and PA subscribers must add state sales tax. Subscriptions from outside the
US and Canada must be prepaid, *in US dollars only*. Rates valid for orders received
before October 31, 1993.

Please allow 8 weeks for delivery of your first issue. Surface mail delivery to
countries outside the US may take up to 16 weeks. Airmail rates available upon
request.

Williams & Wilkins

MOL 54117

P.O. Box 23291
Baltimore, Maryland 21203-9990

Broadway House
2-6 Fulham Broadway
London SW6 1AA England

J3022S ZMOL



**Copyright © 1992 by the American Society for
Pharmacology and Experimental Therapeutics**

INSTRUCTIONS TO AUTHORS

Molecular Pharmacology will publish the results of investigations that contribute significant new information on drug action or selective toxicity at the molecular level. The term "drug" is defined broadly to include chemicals that selectively modify biological function.

Suitable papers are those that describe applications of the methods of biochemistry, biophysics, genetics, and molecular biology to problems in pharmacology or toxicology. Also suitable are reports of fundamental investigations which, although not concerned directly with drugs, nevertheless provide an immediate basis for further study of the molecular mechanism of drug action. Observations of phenomena that shed no light upon underlying molecular interactions are not appropriate for publication. Comparative studies, such as those involving drug-receptor or drug-enzyme interactions that already have been well characterized in other types of cells or tissues, also are inappropriate for publication unless they contribute significant new insight into mechanisms.

Molecular Pharmacology has adopted a uniform policy for evaluation of manuscripts utilizing molecular modeling. Key aspects of content that determine suitability and eventual acceptance include: use of modeling technology to generate predictions concerning new molecules, modeling studies that offer significant new insights into the mechanism of actions of drugs, and inclusion of experimental data that support the predictions of molecular modeling. It is not necessary that each aspect be reflected in every manuscript; however, manuscripts that are purely theoretical in nature or that simply generate structural predictions without correlating these to drug action or new biological data will be returned as unsuitable for publication.

Specific areas of interest include: identification and characterization of receptors for hormones, growth factors, neurotransmitters, toxins, and other drugs; analysis of receptor response pathways; drug effects on metabolic pathways, biosynthesis and degradation of macromolecules, and cellular regulatory mechanisms; analysis of drug-receptor and drug-enzyme interactions; effects of drugs on structure and properties of macromolecules and membranes; relationships between drug structure and activity; molecular mechanisms of drug metabolism; distribution and transport between biological compartments; molecular mechanisms of chemical mutagenesis, carcinogenesis, and teratogenesis; and molecular mechanisms of selective toxicity, drug allergy, and pharmacogenetics.

Page charges. Authors will be billed at the rate of \$40.00 per page after the paper has been published. It is expected that the page charge will be paid if funds are available for that purpose from the author's institution or from the sponsor of this research. Payment of the charge is not a condition for publication. In case of personal financial hardship, page charges will be waived. Neither the editors nor the reviewers will have knowledge as to who has paid the charge, and this payment always will be considered entirely voluntary.

Submission of manuscript. Manuscripts are published in English only and should be sent to **Dr. T. Kendall Harden, Editor, *Molecular Pharmacology*, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-7368, U. S. A.**

The expenses associated with the review of manuscripts submitted to *Molecular Pharmacology* and other ASPET-sponsored journals that are devoted to publishing original research articles have escalated dramatically in recent years because of ever-increasing costs of postage, supplies, and other office expenses, and the growing number of manuscripts submitted for publication. Thus, it has become necessary for ASPET to follow the example of several other scientific societies which have instituted uniform manuscript handling fees. *Therefore, all manuscripts must be accompanied either by a check for \$40 (in U. S. funds drawn on a U. S. bank payable to ASPET) or by a validated purchase order from the authors' institution.* The review process for submitted manuscripts will be delayed until the manuscript handling fee or purchase order is received in the Editor's office. If submission of the manuscript handling fee entails a personal financial hardship to the author(s), the fee will be waived. In that event, the author(s) should submit a request for waiver of the fee when the manuscript is submitted.

Manuscripts should be typewritten double-spaced with ample margins on one side of the paper, 8½ × 11 inches (ca. 215 × 280 mm). Submit four complete copies of the manuscript and four copies of each figure, plus one original drawing or photograph of each figure. Each half-tone figure requires four original drawings or photographs. All pages should be numbered consecutively beginning with the title page. Limit your reference listings to the minimal

number required to document the manuscript adequately. In most instances 30 references or fewer should suffice.

Under usual circumstances reviewers will be instructed to return only their comments to the editorial office and to destroy manuscripts after a final decision on their acceptability has been made. Original drawings and single copies of manuscripts not accepted for publication will be returned to the authors upon request.

It is understood that the manuscripts and the results they contain will not have been published previously and are not being submitted elsewhere. If the submitted manuscript utilizes or makes bibliographic reference to articles in press, copies should be included with the manuscript. Manuscripts are accepted for review with the understanding that all persons listed as authors have given their approval for the submission of the paper; further, that any person cited as a source of personal communications has approved such citation. Written authorization may be required at the Editor's discretion. Articles and any other material published in *Molecular Pharmacology* represent the opinions of the author(s) and should not be construed to reflect the opinions of the Editor(s) and the Publisher. If and when a manuscript is published, it will become the sole property of the Journal.

Authors submitting a manuscript do so on the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused.

Authors are encouraged to submit electronic diskettes of the final version of their manuscripts along with the typed REVISED manuscript. Diskettes produced on IBM or IBM-compatible computers are preferred, but those produced on most Apple/Macintosh or Wang computers can also be converted. The following word processing programs are preferred: XyWrite III Plus, Word Perfect 4.2, 5.0, or 5.1 (IBM or Macintosh), Microsoft Word (IBM or Macin-

tosh), Wang OIS (WPS), and Wordstar (IBM). Among other word processing systems that we can convert are CPT 8000, MacWrite 2.2 or 4.5, Display Write 3 or 4, Multimate, PC Write, Volkswriter, and Write Now. Authors preparing diskettes on Macintosh computers should not use the Fast Save option. Files in ASCII can also be used, but are not preferred. Identify the diskette by providing journal name, manuscript number, senior author's name, manuscript title, name of computer file, type of hardware, operating system and version number, and software program and version number.

The journal does not assume responsibility for errors in conversion of customized software, newly released software, and special characters. Mathematics and tabular material will be processed in the traditional manner.

Accelerated Communications. In order to provide a mechanism for rapid publication of novel experimental findings of unusual and timely significance, manuscripts will be accepted for consideration as Accelerated Communications. Accelerated Communications are not intended for publication of preliminary results. Manuscripts submitted under this category should present novel results that are clearly documented and should make a conceptual advance in their field. They will be reviewed by the same criteria applied to regular papers in *Molecular Pharmacology*. The manuscript should be accompanied by a transmittal letter briefly outlining the significance of the work and providing a list of at least three scientists who would be appropriate reviewers.

Accelerated Communications will be reviewed as rapidly as possible with the aim of reaching an editorial decision within four weeks of receipt of the manuscript. It is expected that Accelerated Communications which are accepted will be published in essentially the form submitted. Manuscripts accepted without revision will be published within four to five months of initial receipt. Manuscripts accepted with a requirement for minor revisions will be published two or three months following receipt of a suitably revised version.

All manuscripts that require major revisions or that do not fit the criteria for Accelerated Communications will be returned to authors for revision and further consideration as a regular paper. Such manuscripts will retain the original submission date if revised versions are received in a timely manner.

Accelerated Communications may be submitted in the same style as regular manuscripts. Results and Discussion may be combined at the discretion of the authors. Manuscripts must not exceed five printed pages in the journal. This corresponds approximately to 25 double-spaced typewritten pages (1-inch margins) including all components of the manuscript and counting each figure as a page of typewritten text. Manuscripts that are judged to be too long will be considered as regular papers.

Organization and style of manuscripts. The policy of the Journal is to allow authors maximum freedom in organizing and presenting their material, and in expressing their ideas, provided only that clarity and conciseness are achieved. For most manuscripts, the most suitable format is: (1) Summary, (2) Introduction, (3) Materials and Methods, (4) Results, and (5) Discussion.

Certain conventions must be observed. Chemical and mathematical formulas and abbreviations should follow the *Instructions to Authors of the Journal of Biological Chemistry* (Vol. 261, pp. 1-11, January 10, 1986). Drugs must be referred to by their generic or chemical names throughout the text, but may be identified by trade name in parentheses or a footnote. The systematic name and number given by the Commission on Enzymes of the International Union of Biochemistry should be included for each enzyme of importance in a paper, at the point in the Summary or Introduction where the enzyme is first mentioned. The use of abbreviations should be minimized and abbreviations avoided in the Summary.

All essential abbreviations should be defined in a single footnote when first introduced. Abbreviations of journal names should conform to the style of *Biological Abstracts*. References to papers that have been accepted for publication, but have not appeared, should be cited like other references with the abbreviated name of the journal followed by the words "in press." Copies of such papers should be sent whenever the findings described in them have a direct bearing on the paper being submitted for publication. "Personal Communications" and "Unpublished Observations" should be cited in footnotes to the text and should not be included in the reference list.

A manuscript should include the following, in the order listed: (1) Title. Numbered footnotes to the title should be avoided; acknowledgment of financial support should be given in an unnumbered footnote to the title. (2) Names of authors, their laboratory and institution. (3) A running title, not exceeding 60 characters and spaces. (4) Summary. (5) Text. Footnotes should be referred to by superscript numbers and references by numbers in parentheses. (6) References, numbered according to order of citation in the text, including title and complete pagination. Examples: 1. Goren, J. H., L. G. Bauge, and W. Vale. Forces and structural limitations of binding of thyrotropin-releasing receptor: the pyroglutamic acid moiety. *Mol. Pharmacol.* 13:606-614 (1977). 2. Chernow, B., and J. T. O'Brian. Overview of catecholamines in selected endocrine systems, in *Norepinephrine* (M. G. Ziegler and C. R. Lake, eds.). Williams and Wilkins, Baltimore, 439-449 (1984). 3. Snedecor, G. W., and W. G. Cochran. *Statistical Methods*. Iowa State University Press, Ames (1967). (7). Footnotes, numbered according to order of appearance in the text. (8) Tables. (9) Figures. (10) Legends to figures. (11) Name and address of person to receive galley proof.

Tables. These should be numbered with arabic numerals and designed to fit the single-column width of the full-page width. Every table should have an explanatory title and sufficient experimental detail in a paragraph following the title to be intelligible without references to the text (unless the procedure is given in the Methods section, or under another table or figure). Footnotes to tables should appear beneath the tables themselves and should be designated by lower-case italic superscript letters, *a*, *b*, *c*, etc.

Figures. These should be numbered with arabic numerals. Each of the four manuscript copies should contain all of the figures. Only the original set need be of quality suitable for reproduction except in the case of half-tones, which require four sets of photographs or original drawings. These should be unmounted glossy photographs (or original India-ink drawings). Usually figures will be reduced to one column width (85 mm) and all numbers after such reduction should be at least 1.5 mm high. The figures must be ready, in all respects, for direct reproduction: no lettering or other art work will be done by the publisher. If symbols are not explained on the face of the figure, only standard characters, of which the printer has type, may be used ($\times$, $\circ$, $\bullet$, $\square$, $\blacksquare$, $\triangle$, $\blacktriangle$, $\odot$). The back of each photograph should bear its number, and the legend TOP at the appropriate edge. The list of legends for the figures should give captions and sufficient experimental detail, as required for tables.

Page proof. Authors will be billed for substantial changes in page proof. The Editors are very much interested in having accepted contributions appear in the earliest possible issue of the Journal, and therefore request that galley proof be returned within 24 hours after its receipt. In exceptional cases, a "Note added in proof" may be attached and will be published if the Editor approves.

Reprints and page charges. An order form for reprints as well as information on the estimation of page charges will be mailed with galley proof. Please direct questions on reprints, page charges, or other business matters to Kay Croker, Executive Officer, American Society for Pharmacology and Experimental Therapeutics, 9650 Rockville Pike, Bethesda, Md. 20814. Telephone (301)530-7060.

Previous Editors

- 1965** Avram Goldstein, *Editor*. Stanford University.
1968 Paul Talalay, *Editor*; Donald S. Coffey, *Associate Editor*. Johns Hopkins University.
1971 Steven E. Mayer, *Editor*, Palmer W. Taylor, *Associate Editor*. University of California at San Diego.
1975 George I. Drummond, *Editor*; H. Joseph Goren, *Associate Editor*. University of Calgary.
1978 Norman Kirschner, *Editor*; Theodore A. Slotkin, *Associate Editor*. Duke University.
1983 Joel G. Hardman, *Editor*; Lee Limbird, F. Peter Guengerich, *Associate Editors*. Vanderbilt University.
1986 William A. Catterall, *Editor*; Joseph A. Beavo, Mont R. Juchau, Neil M. Nathanson, Daniel R. Storm, Frank F. Vincenzi, *Associate Editors*. University of Washington, Seattle.

INFORMATION TO SUBSCRIBERS

MOLECULAR PHARMACOLOGY is published monthly, two volumes a year, beginning in January & July. Instructions to Authors will be found in every issue.

Correspondence concerning business matters should be addressed to Williams & Wilkins, 428 East Preston St., Baltimore, Maryland 21202-3993 U.S.A.

Correspondence regarding editorial matters should be addressed to the Editor, Dr. T. Kendall Harden, CB 7368, Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7368.

Annual Subscription Rates—U. S. A. AND POSSESSIONS: personal, \$100.00; institutional, \$210.00, single copy, \$18.00. FOREIGN: personal, \$130.00; institutional, \$240.00; single copy, \$21.00. (Prices subject to change.) Institutional (multiple reader) rate applies to libraries, schools, hospitals, clinics, group practices, and federal, commercial, and private institutions and organizations. Foreign subscribers who wish to have issues sent by air mail may inquire of the publisher for the additional cost. The GST Tax Number for Canadian subscribers is 123394371.

Change of address: Publisher must be notified 60 days in advance. Journals undeliverable because of incorrect address will be destroyed. Duplicates can be obtained (if available) from the publisher at the regular price of single issues.

New subscriptions are entered to begin with the next issue to publish unless instructed otherwise by the subscriber. Subscriptions run for a 12-month period.

To avoid a break in your series, subscriptions should be renewed promptly. The publisher cannot guarantee to supply back issues on belated renewals.

Reprints of individual articles are available *only* from authors.

Microfilm. For availability, inquire of Williams & Wilkins.

Williams & Wilkins, Baltimore, MD 21202-3993 U. S. A.